Immunotoxins are protein molecules composed of a cell surface-directed ligand covalently linked to a peptide cytotoxin. This definition excludes a number of important therapeutic compounds with distinct pharmacologic properties which react with intracellular targets. Such molecules would be unlikely to find and react with their intracellular targets due to the permeability barrier of the plasma membrane. Thus, the ligands must bind cell surface receptors or antigens. Ligands which have been used include monoclonal antibodies and antibody fragments, adhesion molecules, growth factors, and cytok-ines.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Senekowitsch-Schmidtke R, Schuhmacher C, Becker KF et al. Highly specific tumor binding of a 213Bis-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer. Cancer Res 2001; 61: 2804–8.
Hellstrom I, Hellstrom KF, Senter PD. Development and activities of the BR96-doxorubicin immunoconjugate. Meth Mol Biol 2001; 166: 3 16.
Gottstein C, Wels W, Ober B, Thorpe PE. Generation and characterization of recombinant vascular targeting agents from hybridoma cell lines. Biotechniques 2001; 30: 190–4.
Juhl H, Petrella EC, Cheung NK, Bredehorst R, Vogel CW. Additive cytotoxicity of different monoclonal antibody cobra venom factor conjugates for human neuroblastoma cells. Immunobiology 1997; 197: 444–59.
Schrama D, thor Straten P, Fischer WH et al. Targeting of lympho-toxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 2001; 14: 111–21.
Bhakdi S, Bayley H, Valeva A et al. Staphylococcal alphatoxin, streptolysin-O, and Escherichia coli hemolysin: prototypes of pore-forming bacterial cytolysins. Arch Microbiol 1996; 165: 73–9.
Sears CL, Kaper JB. Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion. Microbial Rev 1996; 60: 167–215.
Schindler J, Sausville E, Messmann R, Uhr JW, Vitetta ES. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin Cancer Res 2001; 7: 255–8.
Tsai LC, Chen YL, Lee C et al. Growth suppression of human colorectal carcinoma in nude mice by monoclonal antibody C27-abrin A conjugate. Dis Colon Rectum 1995; 38: 1067–74.
Tonevitsky AG, Agapov II, Shamshiev AT, Temyakov DE, Pohl P, Kirpichnikov MP. Immunotoxins containing A chain of mistletoe lectin I are more active than immunotoxins with ricin A-chain. FFBS Lett 1996; 392: 166–8.
Rosenblum MG, Shawver LK, Marks JW, Brink J, Cheung L, Langton-Webser B. Recombinant immumotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytodoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models. Clin Cancer Res 1999; 5: 865–74.
Ritter S, Bugarith K, Dinh TT. Immunotoxic destruction of distinct catecholamine subgroups produces selective impairment of gluco-regulatory responses and neuronal activation. J Comp Neurol 2001; 432: 197–216.
Schlick J, Dulieu P, Desvoyes B, Adami P, Radom J, Jouvenot M. Cytotoxic activity of a recombinant GnRH-PAP fusion toxin on human tumor cell lines. FEBS Lett 2000; 472: 241–6.
Ramakrishnan S, Enghlid JJ, Bryant HL, Xu FT. Characterization of a translation inhibitory protein from Luffa aegyptiaca. Biochem Biophys Res Common 1989; 160: 509–16.
Bolognesi A, Polito L, Tazzari PL et al. In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribo-some-inactivating proteins. Br J Haematol 2000; 110: 351–61.
Casellas P, Dussossoy D, Falasca AI et al. Trichokirin, a ribosome-inactivating protein from the seeds of Trichosanthes kirilowii Maximowicz. Purification, partial characterization and use for preparation of immunotoxins. Eur J Biochem 1988; 176: 581–8.
Ovadia, M, Hager, CC, Oeltmann, TN. An anti-melanoma-barley ribosome inactivating protein conjugate is cytotoxic to melanoma cells in vitro. Anticancer Res 1990; 10: 671–5.
Francisco JA, Gawlak SL, Siegall CB. Construction, expression and characterization of BD 1-G28–5 sFv, a single-chain anti-CD40 immunotoxin containing the ribosome-inactivating protein bryodin 1. J Biol Chem 1997; 272: 24165–9.
Porro G, Bolognesi A, Caretto P et al. In vitro and in vivo properties of an anti-CD5-momordin immunotoxin on normal and neoplastic T lymphocytes. Cancer Immunol Immunother 1993; 36: 346–50.
Bolognesi A, Tazzari PL, Tassi C, Groom G, Gobbi M, Stirpe F. A comparison of anti-lymphocyte immunotoxins containing different ribosome-inactivating proteins and antibodies. Clin Exp Immunol 1992; 89: 341–6.
Siegall CB, Gawlak SL, Chace D, Wolf, EA, Mixan B, Marquardt H. Characterization of ribosome-inactivating proteins isolated from Bryonia dioica and their utility as carcinoma-specific immu-noconjugates. Bioconj Chem 1994; 5: 423–9.
Bolognesi A, Tazzari PL, Legname G et al. Anti-CD30 immuno-toxins with native and recombinant dianthin 30. Cancer Immunother Immunother 1995; 40: 109–14.
Gasanov SF, Rael FD, Gasanov NF, Vernon LP. In vitro evaluation of Pyrularia thionin-anti-CD5 immunotoxin. Cancer Immunol Immunother 1995; 41: 122–8.
Huang CA, Yamada K, Murphy MC et al. In vivo T cell depletion in miniature swine using the swine CD3 immunotoxin, pCD3-CRM9. Transplantation 1999; 68: 855–60.
Onda M, Olafsen T, Tsutsumi Y, Bruland OS, Pastan I. Cytotoxicity of anti-osteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A. J Immunother 2001; 24: 144–50.
Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 2001; 276: 17976–84.
Deonarain MP, Epenetos AA. Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribo-nuclease-based immunotoxins. Br J Cancer 1998; 77: 537–46.
Newton DL, Nicholls PJ, Rybak SM, Youle RJ. Expression and characterization of recombinant human eosinophil derived neuro-toxin and eosinophil-derived neurotoxin-antitransferrin receptor sFv. J Biol Chem 1994; 269: 26739–45.
Newton DL, Xue Y, Olson KA, Fett JW, Rybak SM. Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains. Biochemistry 1996; 35: 545–53.
Psarras K, Ueda M, Yamamura T et al. Human pancreatic Rnase l-human epidermal growth factor fusion: an entirely human ‘immunotoxin analog’ with cytotoxic properties against squamous cell carcinomas. Protein Eng 1998; 11: 1285–92.
Gho YS, Chae CB. Luteinizing hormone releasing hormone-RNase A conjugates specifically inhibit the proliferalion of LHRH-receptor-positive human prostate and breast tumor cells. Mol Cells 1999; 9: 31–6.
Newton DL, Hansen HJ, Mikalski SM, Goldenberg DM, Rybak SM. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodg-kin's lymphoma. Blood 2001; 97: 528–35.
Rathore D, Nayak SK, Bator JK. Overproduction of fungal ribot-oxin alpha-sarcin in Escherichia coli: generation of an active immumotoxin. Gene 1997; 190: 311–35.
Goyal A, Batra JK. Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins. Biochem J 2000; 345: 247–54.
Parente D, Raucci G, Celano B, Pacilla et al. Clavin, a type 1 ribo-some-inactivating protein from Aspergillus clavatus IFO 8605. cDNA isolation, heterologous expression, biochemical and biological characterization of the recombinant protein. Eur J Biochem 1996; 239: 272–80.
Chovnick A, Schneider WP Tso JY, Queen C, Chang CN. A recombinant, membrane-acting immunotoxin. Cancer Res 1991; 51: 465–7.
Avila AD, Mateo de Acosta C, Lage A. A carcinoembryonic antigen-directed immunotoxin built by linking a monoclonal antibody to a hemolytic toxin. Int J Cancer 1989; 43: 926–9.
Yoshida S, Ioka D, Matsuoka H, Endo H, Ishii A. Bacteria expressing single-chain immunotoxin inhibit malaria parasite development in mosquitoes. Mol Biochem Parasitol 2001; 113: 89–96.
Gasanov SE, Rael ED, Gasanov NE, Vernon LP. In vitro evaluation of Pyrularia thionin-anti-CD5 immumotoxin. Cancer Immunol Immunother 1995; 41: 122–8.
Halling KC, Halling AC, Murray EE, Ladin BF, Houston LL, Weaver RE. Genomic cloning and characterization of a ricin gene from Ricinus communis. Nucl Acids Res 1985; 13: 8019–33.
Wood KA, Lord JM, Wawrzynczak EI, Piatak M. Preproabrin: genomic cloning, characterization and the expression of the A-chain in Escherichia coli. Eur J Biochem 1991; 198: 723–32.
Eschenburg S, Krauspenhaar R, Mikhailov A, Stoeva S, Betzel C, Voelter W. Primary structure and molecular modeling of mistletoe lectin I from Viscum album. Biochem Biophys Res Commun 1998; 247: 367–72.
Lord JM. Synthesis and intracellular transport of lectin and storage protein precursors in endosperm from castor beans. Eur J Biochem 1985; 146: 403–9.
Montfort W, Villafranca JE, Monzingo AF et al. The three-dimensional structure of ricin at 2.8 Angstroms. J Biol Chem 1987; 262: 5398–403.
Tahirov TH, Lu TH, Liaw YC, Chen YL, Lin JY. Crystal structure of abrin-a at 2.14 Angstroms. J Mol Biol 1995; 250: 354–67.
Krauspenhuar R, Eschenburg S, Perbandt M et al. Crystal structure of mistletoe lectin I from Viscum album. Biochem Biophys Res Commun 1999; 257: 418–24.
Frankel AE, Burbage C, Fu T, Tagge E, Chandler J, Willingham MC. Ricin toxin contains at least three galactose binding sites located in B chain subdomains 1alpha, 1beta, and 2gamma. Biochemistry 1996; 35: 14749–56.
Sleeves RM, Denton ME, Barnard FC, Henry A, Lambert JM. Identification of three oligosaccharide binding sites in ricin. Biochemistry 1999; 38: 11677–85.
Llorente A, Rapak A, Schmidt SL, van Deurs B, Sandvig K. Expression of mutant dynamin inhibits toxicity and transport of endo-cytosed ricin to the Golgi apparatus. J Cell Biol 1998; 140: 553–63.
Grimmer S, Iversen TG, van Deurs B, Sandvig K. Endosome to Golgi transport of ricin is regulated by cholesterol. Mol Biol Cell 2000; 11: 4205–16.
Girod A, Storrie B, Simpson JC et al. Evidence for a COP-independent transport route from the Golgi complex to the endo-plasmic raticulum. Nature Cell Biol 1999; 1: 423–30.
Sandvig K, van Deurs B. Endocytosis and intracellular transport of ricin: recent discoveries. FEBS Lett 1999; 452: 67–70.
Wesche J, Rapak A, Olsnes S. Dependence of ricin toxicity on translocation of the toxin A-chain from the endoplasmic reticulum to the cytosol. J Biol Chem 1999; 274: 34443–9.
Endo Y, Mitsui K, Motizuki M, Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. J Biol Chem 1987; 262: 5908–12.
Gawlak SL, Neubauer M, Klei HE, Chang CYY, Einspahr HM, Siegall CB. Molecular, biological, and preliminary structural analysis of recombinant bryodin 1, a ribosome inactivating protein from the plant Bryonia dioica. Biochemistry 1997; 36: 3095–103.
Savino C, Federici L, Ippoliti R, Lendaro E, Tsernoglou D. The crystal structure of saporin S06 from Saponaria officinalis and its interaction with the ribosome. FEBS Lett 2000; 470: 239–43.
Legname G, Bellosta P, Gromo G et al. Nucleotide sequence of cDNA coding for dianthin 30, a ribosome inactivating protein from Dianthus caryophyllus. Biochim Biophys Acta 1991; 1090: 119–22.
Monzingo AF, Collins EJ, Ernst SR, Irvin JD, Robertus JD. The 2.5 Angstrom structure of pokeweed antiviral protein. J Mol Biol 1993; 233: 705–15.
Husain J, Tickle IJ, Wood SP. Crystal structure of momordin, a type I ribosome inactivating protein from the seeds of Momordica charantia. FEBS Lett 1994; 342: 154–8.
Hosur MV, Nair B, Satyamurthy P, Misquith S, Surolia A, Kannan KK. X-ray structure of gelonin at 1.8 Angstrom resolution. J Mol Biol 1995; 250: 368–80.
Stirpe F, Bailey S, Miller SP, Bodley JW. Modification of ribo-somal RNA by ribosome-inactivating proteins from plants. Nucl Acids Res 1988; 16: 1349–57.
Frankel AE, Welsh P, Richardson J, Robertus JD. Role of arginine 180 and glutamic acid 177 of ricin toxin A chain in enzymatic inac-tivation of ribosomes. Mol Cell Biol 1990; 10: 6257–63.
Greenfield L, Bjorn MJ, Horn G et al. Nucleotide sequence of the structural gene for diphtheria toxin carried by corynebacteriophage beta. Proc Natl Acad Sci USA 1983; 80: 6853–7.
Ratti G, Rappuoli R, Giannini G. The complete nucleotide sequence of the gene coding for diphtheria toxin in the corynephage omega (tox+) genome. Nucl Acids Res 1983; 11: 6589–95.
Cloe S, Bennett MJ, Fujii G et al. The crystal structure of diphtheria toxin. Nature 1992; 357: 216–22.
Bell CE, Eisenberg D. Crystal structure of nucleotide-free diphtheria toxin. Biochemistry 1997; 36: 481–8.
Brooke JS, Cha JH. Molecular characterization of key diphtheria toxin:receptor interactions. Biochem Biophys Res Commun 2000; 275: 374–81.
Louie GV, Yang W, Bowman ME, Choe S. Crystal structure of the complex of diphtheria toxin with an extracellular fragment of its receptor. Mol Cell 1997; 1: 67–78.
Cha J, Brooke JS, Ivey KN, Eidels L. Cell surface monkey CD9 antigen is a coreceptor that increases diphtheria toxin sensitivity and diphtheria toxin receptor affinity. J Biol Chem 2000; 275: 6901–7.
Shishido Y, Sharma KD, Higashiyama S, Klagsbrun M, Mekada E. Heparin-like molecules on the cell surface potentiate binding of diphtheria toxin to the diphtheria toxin receptor/membrane-anchored heparin-binding epidermal growth factor-like growth factor. J Biol Chem 1995; 270: 29578–85.
Lanzrein M, Sand O, Olsnes S. GPI-anchored diphtheria toxin receptor allows membrane translocation of the toxin without detectable ion channel activity. EMBO J 1996; 15: 725–34.
Almond BD, Eidels L. The effect of receptor rapid-internaliza-tion signals on diphtheria toxin endocytosis and cell sensitivity. Mol Microbiol 1995; 18: 623–30.
Simpson JC, Smith DC, Roberts LM, Lord JM. Expression of mutant dynamin protects cells against diphtheria toxin but not against ricin. Exp Cell Res 1998; 239: 293–300.
Lemichez E, Bomsel M, Devilliers G et al. Membrane translocation of diphtheria toxin fragment A exploits early to late endo-some trafficking machinery. Mol Microbiol 1997; 23: 445–57.
Gordon V, Klimpel K, Arora N, Henderson M, Leppla S. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect Immum 1995; 63: 82–7.
Silverman JA, Mindell JA, Finkelstein A, Shen WH, Collier RJ. Mutational analysis of the helical hairpin region of diphtheria toxin transmembrane domain. J Biol Chem 1994; 269: 22524–32.
Falnes PO, Sandvig K. Penetration of protein toxins into cells. Curr Opin Cell Biol 2000; 12: 407–13.
Falnes PO, Choe S, Madshus IH, Wilson BA, Olsnes S. Inhibition of membrane translocation of diphtheria toxin A-fragment by internal disulfide bridges. J Biol Chem 1994; 269: 8402–7.
Papini E, Rappuoli R, Murgia M, Montecucco C. Cell penetration of diphtheria toxin. Reduction of the interchain disulfide bridge is the rate-limiting step of translocation in the cytosol. J Biol Chem 1993; 268: 1567–74.
Falnes PO, Olsnes S. Cell-mediated reduction and incomplete membrane translocation of diphtheria toxin mutants with internal disulfides in the A fragment. J Biol Chem 1995; 270: 20787–93.
Falnes PO, Ariansen S, Sandvig K, Olsnes S. Requirement for prolonged action in the cytosol for optimal protein synthesis inhibition by diphtheria toxin. J Biol Chem 2000; 275: 4363–8.
Bodley JW, Dunlop PC, Van Ness BG. Diphthamide in elongation factor 2: ADP-ribosylation, purification, and properties. Methods Enzymol 1984; 106: 378–87.
Domenighini M, Rappuoli R. Three conserved consensus sequences identify the NAD-binding site of ADP-ribosylating enzymes, expressed by eurkaryotes, bacteria and T-even bacte-riophages. Mol Microbiol 1996; 21: 667–74.
Bell CE, Eisenberg D. Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. Biochemistry 1996; 35: 1137–49.
Wilson KS, Noller HF. Molecular movement inside the transla-tional engine. Cell 1998; 92: 337–49.
Gomez-Lorenzo MG, Spahn CMT, Agrawal RK et al. Three-dimensional cryo-electron microscopy localization of EF2 in the Saccharomyces cerevisiae 80S ribosome at 17.5A resolution. EMBO J 2000; 19: 2710–8.
Brinkmanm U, Brinkmanm E, Gallo M, Scharf U, Pastan I. Role of CAS, a human homologue to the yeast chromosome segregation gene CSEI, in toxin and tumor necrosis factor mediated apoptosis. Biochemistry 1996; 35: 6891–9.
Keppler-Hafkemeyer A, Brinkmann U, Pastan I. Role of caspases in immunotoxin-induced apoptosis of cancer cells. Biochemistry 1998; 37: 16934–42.
Yamaizumi M, Mekada E, Uchida T, Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 1978; 17: 245–50.
Merion M, Schlesinger P, Brooks RM, Moehring JM, Moehring TJ, Sly WS. Defective acidification of endosomes in Chinese hamster ovary cell mutants cross-resistant: to toxins and viruses. Proc Nad Acad Sci USA 1983; 80: 5315–9.
Foley BT, Moehring JM, Moehring TJ. Mutations in the elongation factor 2 gene which confer resistance to diphtheria toxin and Pseudomonas exotoxin A. Genetic and biochemical analysis. J Biol Chem 1995; 270: 23218–25.
Chung DW, Collier RJ. The mechanism of ADP-ribosylation of elongation factor 2 catalyzed by fragment A from diphtheria toxin. Biochim Biophys Acta 1977; 483: 248–57.
Better M, Bernhard SL, Lei SP Fishwild DM, Carroll SF. Activity of recombinant mitogillin and mitogillin immunoconjugates. J Biol Chem 1992; 267: 16712–8.
Fernandez-Luna JL, Lopez-Otin C, Soriano F, Mendez E. Complete amino acid sequence of the Aspergillus cytotoxin mito-gillin. Biochemistry 1985; 24: 861–7.
Gray GL, Smith DH, Baldridge JS et al. Cloning, nucleotide sequence, and expression in Escherichia coli of the exotoxin A structural gene of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 1984; 81: 2645–9.
Allured VS, Collier RJ, Carroll SF, McKay DR Structure of exo-toxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. Proc Natl Acad Sci USA 1986; 83: 1320–4.
Hessler JL, Kreitman RJ. An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry 1997; 36: 14577–82.
Kounnas MZ, Morris RE, Thompson MR, FitzGerald DJ, Strickland DK, Saelinger CB. The α2-macroglobulin receptor/ low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A. J Biol Chem 1992; 267: 12420–23.
Jinno Y, Chaudhary VK, Kondo T, Adhya S, Pastan I. Mutational analysis of domain I of Pseudomonas exotoxin. Mutations in domain I of Pseudomonas exotoxin which reduce cell binding and animal toxicity. J Biol Chem 1988; 263: 13203–7.
Manhart MD, Morris RE, Bonventre IT, Leppla S, Saelinger CB. Evidence for Pseudomonas exotoxin A receptors on plasma membrane of toxin-sensitive LM fibroblasts. Infect Immun 1984; 45: 596–603.
Ogata M, Fryling CM, Pastan I, FitzGerald DJ. Cellmediated cleavage of Pseudomonas exotoxin between Arg279 and G1y280 generates the enzymatically active fragment which translocates to the cytosol. J Biol Chem 1992; 267: 25396–401.
Inocencio NM, Moehring JM, Moehring TJ. Furin activates Pseudomonas exotoxin A by specific cleavage in vivo and in vitro. J Biol Chem 1994; 269: 31831–5.
McKee ML, FitzGerald DJ. Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story. Biochemistry 1999; 38: 16507–13.
Ogata, M, Chaudhary VK, Pastan, I, FitzGerald, DJ. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J Biol Chem 1990; 265: 20678–85.
Jackson ME, Simpson JC, Girod A, Pepperkok R, Roberts LM, Lord JM. The KDEL retrieval system is exploited by Pseudomonas exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum. J Cell Sci 1999; 112: 467–75.
Kreitman RJ, Pastan I. Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 1995; 307: 29–37.
Hwang J, FitzGerald DJ, Adhya S, Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E coli. Cell 1987; 48: 129–36.
Theuer C P, Buchner J, FirzGerald D, Pastan I. The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion. Proc Natl Acad Sci USA 1993; 90: 7774–8.
Zdanovsky AG, Chiron M, Pastan I, FitzGerald DJ. Mechanism of action of Pseudomonas exotoxin. Identification of a rate-limiting step. J Biol Chem 1993; 268: 21791–9.
Taupiac MP, Bahian M, Alarm M, Beaumelle B. A deletion within the translocation domain of Pseudomonas exotoxin A enhances translocation efficiency and cytotoxicity concomitantly. Mol Microbiol 1999; 31: 1385–93.
Carroll SF, Collier RJ. Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. J Biol Chem 1987; 262: 8707–11.
Li M, Dyda F, Benhar I, Pastan I, Davies DR. Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: implications for the activation process and for ADP ribosylation. Proc Natl Acad Sci USA 1996; 93: 6902–6.
Laithwaite JE, Benn SJ, Yamate J, FitzGerald DJ, LaMarre J. Enhanced macrophage resistance to Pseudomonas exotoxin A is correlated with decreased expression of the low density lipopro-tein-related protein. Infect Immun 1999; 67: 5827–33.
Laurie SM, Robbins AR. A toxin-resistant mouse L-cell mutant defective in protein transport along the secretory pathway. J Cell Physiol 1991; 147: 215–23.
Banker DE, Pastan I, Gottesman MM, Herschman HR. An epidermal growth factor ricin A chain (EGF-RTA)-resistant mutant and an epidermal growth factor Pseudomonas exotoxin (EGF-PE)-resistant mutant have distinct phenotypes. J Cell Physiol 1989; 139: 51–7.
Merion M, Schlesinger P, Brooks RM, Moehring JM, MoehringTJ, Sly WS. Defective acidification of endosomes in Chinese hamster ovary cell mutants ‘cross-resistant’ to toxins and viruses. Proc Natl Acad Sci USA 1983; 80: 5315–9.
Spence MJ, Sicic JF, Foley BT, Moehring TJ. Analysis of mutants in alleles of the fur gene from an endoprotease-deficient Chinese hamster ovary cell strain. Somat Cell Mol Genet 1995; 21: 1–18.
Welkos SL, Lowe JR, Eden-McCutchan F, Vodkin M, Leppla SH, Schmidt JJ. Sequence and analysis of the DIVA encoding protective antigen of Bacillus anthracis. Gene 1988; 69: 287–300.
Petrosa C, Collier RJ, Klimpel KR, Leppla SH, Liddington RC. Crystal structure of the anthrax toxin protective antigen. Nature 1997; 385: 833–8.
Little SF, Novak JM, Lowe JR et al. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 1996; 142: 707–15.
Varughese M, Teixerira AV, Liu S, Leppla SH. Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect Immun 1999; 67: 1860–5.
Friedlander AM, Bhatnagar R, Leppla SH, Johnson L, Singh Y. Characterization of macrophage sensitivity and resistance to anthrax lethal toxin. Infect Immun 1993; 61: 245–52.
Gordon VM, Rehemtulla A, Leppla SH. A role for PACE4 in the proteolytic activation of anthrax toxin protective antigen. Infect Immun 1997; 65: 3370–5.
Robertson DL, Tippetts MT, Leppla SH. Nucleotide sequence of the Bacillus anthracis edema factor gene (cya): a calmodulin-dependent adenylate cyclase. Gene 1988; 73: 363–71.
Bragg TS, Robertson D. Nucleotide sequence and analysis of the lethal factor gene (lef) from Bacillus anthracis. Gene 1989; 81: 45–54.
Drum CL, Yan SZ, Sarac R et al. An extended conformation of calmodulin induces interactions between the structural domains of adenylyl cyclase from Bacillus anthracis to promote catalysis. J Biol Chem 2000; 275: 36334–40.
Labruyere E, Mock M, Surewicz WK et al. Structural and ligand-binding properties of a truncated form of Bacillus anthracis ade-nylate cyclase and of a catalytically inactive variant in which glutamine substitutes for lysine-346. Biochemistry 1991; 30: 2619–24.
Escuyer V, Duflot E, Sezer O, Danchin A, Mock M. Structural homology between virulence-associated bacterial adenylate cyclases. Gene 1988; 71: 293–8.
Leppla SH. Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eucaryotic cells. Adv Cyclic Nucl Protein Phosphor Res 1984; 17: 189–98.
Gupta P, Singh A, Chauhan V, Bhathagar R. Involvement of residues 147VYYE-IGK153 in binding of lethal factor to protective antigen of Bacillus anthracis. Biochem Biophys Res Commun 2001; 280: 158–63.
Quinn CP, Singh Y, Klimpel KR, Leppla SH. Functional mapping of anthrax toxin lethal factor by in-frame insertion mutagenesis. J Biol Chem 1991; 266: 20124–30.
Duesbery NS, Webb CP, Leppla SH et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998; 280: 734–7.
Singh Y, Klimpel KR, Goel S, Swain PK, Leppla SH. Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. Infect Immun 1999; 67: 1853–9.
Gordon VM, Leppla SH, Hewlett EL. Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis ade-nylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect Immun 1988; 56: 1066–9.
Miller CJ, Elliott JL, Collier RJ. Anthrax protective antigen: prepore-to-pore conversion. Biochemistry 1999; 38: 10432–8.
Sellman BR, Mourez M, Collier RJ. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science 2001; 292: 695–7.
Batra S, Gupta P, Chauhan V, Singh A, Bhatnagar R. Trp 346 and Leu 352 residues in protective antigen are required for the expression of anthrax lethal toxin activity. Biochem Biophys Res Commun 2001; 281: 186–92.
Rossi AG, McCutcheon JC, Roy N, Chilvers ER, Haslett C, Dransfield I. Regulation of macrophage phagocytosis of apop-totic cells by cAMP. J Immunol 1998; 160: 3562–8.
Duesbery NS, Webb CP, Vande Woude GF. MEK wars, a new front in the battle against cancer. Nature Med 1999; 5: 736–7.
Boix E, Leonidas DD, Nikolovski Z, Nogues MV, Cuchillo CM, Acharya KR. Crystal structure of eosinophil cationic protein at 2.4 Angstrom resolution. Biochemistry 1999; 38: 16794–801.
Fersht A. Enzyme Structure and Mechanism. New York: Freeman 1985: 426–31.
Antignani A, Naddeo M, Cubellis MV, Russo A, D'Alessio G. Antitumor action of seminal ribonuclease, its dimeric cytosolic ribonuclease inhibitor. Biochemistry 2001; 40: 3492–6.
Leonidas DD, Boix E, Pril R et al. Mapping the ribonucleolytic active site of eosinophil-derived neurodoxin (EDN). J Biol Chem 2001; 276: 15009–17.
Hu GF, Xu CJ, Riordan JF. Human angiogenin is rapidly translocated to the nucleus of human umbilical vein endothelial cells and binds to DNA. J Cell Biochem 2000; 76: 452–62.
Bretscher LE, Abel RL, Raines RT. A ribonuclease A variant with low catalytic activity but high cytodoxicity. J Biol Chem 2000; 275: 9893–6.
Yang X, Moffat K. Insights into specificity of cleavage and mechanism of cell entry from the crystal structure of the highly specific Aspergillus ribotoxin, restrictocin. Structure 1996; 4: 837–52.
Perez-Canadillas JM, Santoro I, Campos-Olivas R et al. The highly refined solution structure of the cytotoxic ribonuclease α-sarcin reveals the structural requirements for substrate recognition and ribonucleolytic activity. J Mol Biol 2000; 299: 1061–73.
Szewczak AA, Moore PB. The sarcin/ricin loop, a modular RNA. J Mol Biol 1995; 247: 81–98.
Naylor CE, Eaton IT, Howells A et al. Structure of the key toxin in gas gangrene. Nature Struct Biol 1998; 5: 738–46.
de los Rios V, Onaderra M, Martinez-Ruiz A et al. Overproduction in Escherichia coli and purification of the hemolytic protein sticholysin II from the sea anemone Stichodactyla helianthus. Protein Express Purif 2000; 18: 71–6.
Mancheno JM, De los Rios V, Del Pozo AM, Lanio ME, Onaderra M, Gavilanes JG. Partially folded states of the cytolytic protein sticholysin II. Biochim Biophys Acta 2001; 1545: 122–31.
Martin-Benito J, Gavilanes F, de los Rios V, Mancheno JM, Fernandez JJ, Gavilanes JG. Two-dimensional crystallization on lipid monolayers and three-dimensional structure of stricholysin II, a cytolysin from the sea anemone Stichodactyla helianthus. Biophys 1 2000; 78: 3186–94.
Moore Al, Beazley WD, Bibby MC, Devine DA. Antimicrobial activity of cecropins. J Antimicrob Chemother 1996; 37: 1077–89.
Jaynes JM, Burton CA, Barr SB et al. In vitro cytocidal effect of novel lytic peptides on Plasmodium falciparum and Trypanosoma cruzi. FASEB J 1988; 2: 2878–83.
Vernon LP. Pyrularia thionin: physical properties, binding to phospholipid bilayers, and cellular responses. Adv Exp Med Biol 1996; 391: 279–91.
Gasnov SE, Vernon LP, Aripov TF. Modification of phospholipid membrane structure by the plant toxic peptide Pyrularia thionin. Arch Biochem Biophys 1993; 301: 367–74.
Wang F, Naisbitt GH, Vernon LP, Glaser M. Pyrularia thionin binding to and the role of tryptophan-8 in the enhancement of phosphatidylserine domains in erythrocyte membranes. Biochemistry 1993; 32: 12283–9.
Gould BJ, Borowitz MJ, Groves ES et al. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies. J Nat Cancer Inst 1989; 81: 775–81.
Grossbard ML, Gribben JG, Freedman AS et al. Adjuvant immu-motoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 1993; 81: 2263–71.
Frankel AE, Fu T, Burbage C, Chandler J, Willingham MC, Tagge EP. IL2 fused to lectin-deficient ricin is toxic to human leukemia cells expressing the IL2 receptor. Leukemia 1997; 11: 22–30.
Gilliland DG, Steplewski Z, Collier RJ, Mitchell KF, Chang TH, Koprowski H. Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci USA 1980; 77: 4539–43.
Loberboum-Galski H, Garsia RJ, Gately M et al. IL2-PE664G1u, a new chimeric protein cytodoxic to human activated T lymphocytes. J Biol Chem 1990; 265: 16311–7.
Frankel AE, Powell BL, Vallera DA, Neville DM. Chimeric fusion proteins (diphtheria toxin-based). Curr Opin Invest Drug 2001; 2: 1294–301.
Kreitman RJ, Pastan I. Recombinant toxins. Adv Pharmacol 1994; 28: 193–219.
Varughese M, Teixeira AV, Liu S, Leppla SH. Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect Immum 1999; 67: 1860–5.
Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 2001; 276: 17976–84.
Aqeilan R, Yarkoni S, Lorberboum-Galski H. Interleukin 2-Bax: a novel prototype of human chimeric proteins for targeted therapy. FEBS Lett 1999; 457: 271–6.
Thompson J, Stavrou S, Weetall M et al. Improved binding of a bivalent single-chain immumotoxin results in increased efficacy for in vivo T-cell depletion. Protein Eng 2001; 14: 1035–41.
Vallera DA, Kuroki DW, Panoskaltsis-Mortari A, Buchsbaum DJ, Rogers BE, Blazar BR. Molecular modification of a recombinant anti-CD3e-directed immumotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model. Blood 2000; 96: 1157–65.
Vallera DA, Panoskaltsis-Mortari A, Jost C et al. Anti-graft-versus-host disease effect of DT390-anti-CD3sFv; a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor. Blood 1996; 88: 2342–53.
Colombatti M, Greenfield L, Youle RJ. Cloned fragment of DT linked to T-cell specific antibody identifies regions of B chain active in cell entry. J Biol Chem 1986; 261: 3030–5.
Neville DM, Scharf, J, Srinivasachar K. In vivo T-cell ablation by a halo-immunotoxin directed at human CD3. Proc Natl Acad Sci USA 1992; 89: 2585–9.
Neville DM, Scharff J, Hu HZ. A new reagent for the induction of T cell depletion, anti-CD3-CRM9. J Immunother 1996; 19: 85–92.
Ek O, Waurzyniak B, Myers DE, Uckun FM. Antitumor activity of TP3 (anti-p80)-pokeweed antiviral protein immunotoxin in hamster cheek pouch and severe combined immumodeficient mouse xenograft models of human osteosarcoma. Clin Cancer Res 1998; 4: 1641–7.
Shaw JP Akiyoshi DE, Arrigo DA et al. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J Biol Chem 1991; 266: 13449–55.
Cawley DR Herschman HR. Epidermal growth factor toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic. Cell 1980; 22: 563–70.
Williams DP Snider CE, Strom TR Murphy JR. Structure/function analysis of interleukin-2 toxin (DAB486IL-2): fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 1990; 265: 11885–9.
Lorberboum-Galski H, Kozak RW, WaldmannTA, Bailm P, FitzGerald DJ, Pastan I. Interleukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor. J Biol Chem 1988; 263: 18650–6.
Kreitman RJ, Pastan I. Recombinant toxins containing human granulocyte macrophage colony-stimulating factor and either Pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells. Blood 1997; 90: 252–9.
Perentesis JP, Bendel AE, Shan Y et al. Granulocyte macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy-and radiation-resistant human myeloid leukemias. Leuk Lymph 1997; 25: 247–56.
Burbage C, Tagge EP, Harris B et al. Ricin fusion toxin targeted to the human granulocyte macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells. Leuk Res 1997; 21: 681–90.
Chan C-H, Blazar BR, Eide CR, Kreitman RJ, Vallera DA. A murine cytokine fusion toxin specifically targeting the murine granulocyte macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-dependent tumor cells. Blood 1995; 86: 2732–40.
Rozemuller H, Rombouts EJC, Touw IP et al. In vivo targeting of leukemia cells using diphtheria toxin fused to murine GM-CSF. Leukemia 1998; 12: 710–7.
Frankel AE, Ramage J, Kiser M, Alexander R, Kucera G, Miller MS. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng 2000; 13: 575–81.
Chan CH, Blazar BR, Greenfield L, Kreitman RJ, Vallera DA. Reactivity of murine cytokine fusion toxin, diphtheria toxin390-murine interleukin-3 (DT390-mIL-3), with bone marrow progenitor cells. Blood 1996; 88: 1445–56.
Liger D, vanderSpek JC, Gaillard C et al. Characterization and receptor specific toxicity of two diphtheria toxin-related interleu-kin-3 fusion proteins DAB389-mIL3 and DAB389-(G4S)2-mIL3. FEBS Lett 1997; 406: 157–61.
Neville DM, Srinivasachar K, Stone R, Scharf, J. Enhancement of immunotoxin efficacy by acid-cleavable cross-linking agents utilizing diphtheria toxin and toxin mutants. J Biol Chem 1989; 264: 14653–61.
Johnson VG, Wrobel C, Wilson D et al. Improved tumor specific immunotoxins in the treatment of CNS and leptomeningeal neo-plasia. J Neurosurg 1989; 70: 740–8.
Bjorn M, Ring D, Frankel AE. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res 1985; 45: 1214–21.
Newton DL, Ilercil O, Laske DW, Oldfield E, Rybak SM, Youle RJ. Cytotoxic ribonuclease chimeras. Targeted tumoricidal activity in vitro and in vivo. J Biol Chem 1992; 267: 19572–8.
Pirker R, FitzGerald DJ, Willingham MC, Pastan I. Enhancement of the activity of immunotoxins made with either ricin A chain or Pseudomonas exotoxin in human ovarian and epidermoid carcinoma cell lines. Cancer Res 1988; 48: 3919–23.
Francis JW, Brown RH, Figueredo D et al. Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: a potential vector for delivering het-erologous proteins to neurons. J Neurochem 2000; 74: 2528–36.
Fisher CE, Sutherland JA, Krause JE, Murphy JR, Leeman SE, vanderSpek JC. Genetic construction and properties of a diphtheria toxin-related substance P fusion protein: in vitro destruction of cells bearing substance P receptors. Proc Natl Acad Sci USA 1996; 93: 7341–5.
Masood R, Lunardi-Iskandar Y, Jean LF et al. Inhibition of AIDS-associated Kaposi's sarcoma cell growth by DAB389-interleukin 6. AIDS Res Human Retroviruses 1994; 10: 969–75.
Siegall CB, Kreitman RJ, FitzGerald DJ, Pastan I. Anti tumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice. Cancer Res 1991; 51: 2831–6.
Arom N, Masood R, Zheng T, Cai J, Smith DL, Gill PS. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 1999; 59: 183–8.
Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-l-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996; 56: 1324–30.
Veenendaal LM, Jin H, Ran S et al. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovas-culature of solid tumors. Proc Natl Acad Sci USA 2002; 99: 7866–71.
Marsh JW. Antibody-mediated routing of diphtheria toxin in murine cells results in a highly efficacious immumotaxin. J Biol Chem 1988; 263: 15993–9.
Sweeney ER Foss FM, Murphy JR, vanderSpek JC. Interleukin 7 (IL-7) receptor-specific cell killing by DAB389IL-7: a novel agent for the elimination of IL-7 receptor positive cells. Bioconj Chem 1998; 9: 201–7.
Cawley DR Simpson DL, Herschman HR. Asialoglycopro tein receptor mediates the toxic effects of an asialoetuin diphtheria toxin fragment A conjugate on cultured rat hepatocytes. Proc Natl Acad Sci USA 1981; 78: 3383–7.
Cai J, Zheng T, Murphy J, Waters CA, Lin GY, Gill PS. IL4R expression in AIDS-KS cells and response to rhIL-4 and IL-4 toxin (DAB389-IL-4). Invest New Drugs 1997; 15: 279–87.
Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin-4 Pseudomonas exotoxin in patients with highgrade glioma. Clin Cancer Res 2000; 6: 2157–65.
Vallera DA, Jin N, Baldrica JMR, Panoskaltsis-Mortari A, Chen SY, Blazar BR. Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene. Cancer Res 2000; 60: 976–84.
Lakkis F, Steele A, Pacheco-Silva A, Rubin-Kelley V, Strom TB, Murphy JR. Interleukin 4 receptor targeted cytotoxicity: genetic construction and in vivo immunosuppressive activity of a diphtheria toxin-related murine interleukin 4 fusion protein. Eur J Immumol 1991; 21: 2253–8.
Puri RK, Ogata M, Leland P, Feldman GM, FitzGerald D, Pastan I. Expression of high-affinity interleukin 4 receptors on murine sarcoma cells and receptor-mediated cytotoxicity of tumor cells to chimeric protein between interleukin 4 and Pseudomonas exotoxin. Cancer Res 1991; 51: 3011–7.
Puri RK, Leland P, Obiri NI et al. Targeting of interleukin 13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 1996; 87: 4333–9.
Wen Z, Tao X, Lakkis F, Kiyokawa T, Murphy JR. Diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion toxin. J Biol Chem 1991; 266: 12289–93.
Murphy JR, Bishai W, Borowski M, Miyanohara A, Boyd J, Nagle S. Genetic construction, expression and melanoma selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein. Proc Natl Acad Sci USA 1986; 83: 8358–62.
vanderSpek JC, Sutherland JA, Zang H, Battey JF, Jensen RT, Murphy JR. Diphtheria toxin-related fusion protein DAB389GRP. Cancer Res 1997; 57: 290–4.
Negro A, Skaper SD. Synthesis and cytotoxic profile of a diphtheria toxin neurotrophin 4 chimera. J Neurochem 1997; 68: 554–63.
Aullo P, Alcam J, Popoff MR, Klatzmann DR, Murphy JR, Boquet PA. A recombinant diphtheria toxin related human CD4 fusion protein specifically kills HIV infected cells which express gp120 but selects fusion toxin resistant cells which carry HIV. EMBO J 1992; 11: 575–83.
Davey RT, Boenning CM, Herpin BR et al. Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect Dis 1994; 170: 1180–8.
Landgraf R, Pegram M, Slamon DJ, Eisenberg D. Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta 1. Biochemistry 1998; 37: 3220–8.
Gilliland DG, Collier RJ, Moehring JM, Moehring TJ. Chimeric toxins: toxic, disulfide-linked conjugate of conconavalin A with fragment A from diphtheria toxin. Proc Natl Acad Sci USA 1978; 75: 5319–23.
Yamaguchi T, Kato R, Beppu M et al. Preparation of concanava-lin A ricin A-chain conjugate and its biologic activity against various cultured cells. J Natl Cancer Inst 1979; 62: 1387–95.
Bacha P, Murphy JR, Reichlin S. Thyrotropin-releasing hormone diphtheria toxin-related polypeptide conjugates. J Biol Chem 1983; 258: 1565–70.
Youle RJ, Neville DM. Receptor-mediated transport of the hybrid protein ricin diphtheria toxin fragment A with subsequent ADP-ribosylation of intracellular elongation factor II. J Biol Chem 1979; 254: 11089–96.
vanderSpek JC, Sutherland J, Sampson E, Murphy JR. Genetic construction and characterization of the diphtheria toxin-related interleukin 15 fusion protein DAB389sIL15. Protein Eng 1995; 8: 1317–21.
Bernhard MI, Foon KA, Oeltmann TN et al. Guinea pig line 10 hepatocarcinoma model: characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain. Cancer Res 1983; 43: 4420–8.
Uchida T, Yamaizumi M, Mekada E et al. Reconstitution of hybrid toxin from fragment A of diphtheria toxin and a subunit of Wistaria floribunda lectin. J Biol Chem 1978; 253: 6307–10.
Chang TM, Dazord A, Neville DM. Artificial hybrid protein containing a toxic protein fragment and a cell membrane receptorbinding moiety in a disulfide conjugate. J Biol Chem 1977; 252: 1515–22.
Chadwick DE, Williams DP, Niho Y, Murphy JR, Minden MD. Cytotoxicity of a recombinant diphtheria toxin granulocyte colony-stimulating factor fusion protein on human leukemic blast cells. Leuk Lymph 1993; 11: 249–62.
Tojo A, Oshima Y. Targeted toxin therapy in the treatment of leukemia. Jpn J Clin Hematol 1995; 36: 578–81.
Bound TF, Wang QC, Reisfeld RA, Kaplan NO. Monoclonal antibody and an antibody toxin conjugate to a cell surface proteo-glycan of melanoma cells suppress in vivo tumor growth. Proc Nad Acad Sci USA 1983; 80: 529–33.
Monaco ME, Mack J, Dugan MD, Ceriani R. An antibody toxin conjugate directed against a human mammary cancer antigen. Ann NY Acad Sci 1986; 464: 389–99.
Gilliland DG, Steplewski Z, Collier RJ, Mitchell KF, Chang TH, Koprowski H. Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci USA 1980; 77: 4539–43.
Hertler AA, Schlossman DM, Borowitz MJ, Blythman HE, Casellas P, Frankel AE. An anti-CD5 immunotoxin for chronic lymphocytic leukemia: enhancement of cytotoxicity with human serum albumen-monenstn. Int J Cancer 1989; 43: 215–9.
Villemez CL, Carlo PL. Preparation of an immunotoxin for Acanthamoeba castellanii. Biochem Rophys Res Common 1984; 125: 25–9.
Moolten FL, Capparall NJ, Zajdel SH, Cooperband SR. Antitumor effects of antibody-diphtheria toxin conjugates. II. Immunotherapy with conjugates directed against tumor antigens induced by simian virus 40. J Natl Cancer Inst 1975; 55: 473–7.
Mannhalter JW, Gilliland DG, Collier RJ. A hybrid toxin containing fragment A from diphtheria toxin linked to the B protomer of cholera toxin. Biochim Biophys Acta 1980; 626: 443–50.
Gilliland DG, Collier RJ. A model system involving anti-conconava-lin A for antibody targeting of diphtheria toxin fragment Al. Cancer Res 1980; 40: 3564–9.
Gilliland DG, Collier RJ. Characterization of hybrid molecules containing fragment A from diphtheria toxin linked to concanav-alin A or the binding subunit of ricin toxin. J Biol Chem 1981; 256: 12731–9.
Pederzolli C, Belmonte G, Dalla Serra M, Macek P, Menestrina G. Biochemical and cytotoxic properties of conjugates of trans-ferrin with equinatoxin II, a cytolysin from a sea anemone. Bioconj Chem 1995; 6: 166–73.
Bera TK, Kennedy PE, Berger EA, Barbas CF, Pastan I. Specific killing of HIV-infected lymphocytes by a recombinant immuno-toxin directed against the HIV-1 envelope glycoprotetn. Mol Med 1998; 4: 384–91.
Pincus SH, Wehrly K, Cole R et al. In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160. AIDS Res Human Retroviruses 1996; 12: 1041–51.
Bjorn MJ, Groetsema G. Immunotoxins to the murine transferrin receptor: intracavitary therapy of mice bearing syngeneic peritoneal tumors. Cancer Res 1987; 47: 6639–45.
Ghetie MA, Morarn I, Margineanu M, Ghetie V. Protein A vectorized toxins II. Preparation and ‘in vitro’ cytotoxic effect of protein A-ricin A chain conjugate on antibody coated human tumour cells. Mol Immunol 1988; 25: 473–7.
Erice A, Balfour HH, Myers DE et al. Anti-human immunodefi-ciency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein. Antimicrob Agents Chemother 1993; 37: 835–8.
Wawrzynczak EJ, Watson GJ, Cumber AJ et al. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immuno-toxin. Cancer Immunol Immunother 1991; 32: 289–95.
Woo BH, Lee IT, Na DH, Lee KC. Sepharose-unbinding ricin E as a source for ricin A chain immunotoxin. J Immunol Meth 2001; 249: 91–8.
Pai LH, Bookman MA, Ozols RE et al. Clinical evaluation of intra-peritoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 1991; 9: 2095–103.
Bjorn MJ, Manger R, Sivam G, Morgan AC, Torok-Storb B. Selective elimination of breast cancer cells from human bone marrow using an antibody Pseudomonas exotoxin A conjugate. Cancer Res 1990; 50: 5992–6.
Rajagopal V, Kreitman RJ. Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha2-macroglobulin receptor. J Biol Chem 2000; 275: 7566–73.
Cavallaro U, del Vecchio A, Lappi DA, Soria MR. A conjugate between human urokinase and saporin, a type-1 ribosome-inacti-vating protein, is selectively cytotoxic to mokinase receptor-expressing cells. J Biol Chem 1993; 268: 23186–90.
Vallera DA, Li C, Jin N, Panoskaltsis-Mortari A, Hall WA. Targeting overexpressed urokinase-type plasminogen activator receptor (uPAR) on human glioblastoma with the diphtheria toxin fusion protein DTAT in nude mice. J Natl Cancer Inst 2002; 94: 597–606.
Li C, Hall WA, Vallera DA. Diphtheria toxin 390/IL13 fusion protein selectively targets receptor expressing human glioblastoma growing in nude mice. Protein Eng 2002; 15: 419–27.
Yang D, Krum CT, Payne J et al. Recombinant heregulin Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo. Clin Cancer Res 1998; 4: 993–1004.
Gawlak SL, Pastan I, Siegall CB. Basic fibroblast growth factor Pseudomonas exotoxin chimeric proteins; comparisons with acidic fibroblast growth factor Pseudomonas exotoxin. Bioconj Chem 1993; 4: 483–9.
Brinkmanm U, Gallo M, Brinkmann E, Kunwar S, Pastan I. A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin. Proc Nad Acad Sci USA 1993; 90: 547–51.
Mickisch GH, Pai LH, Siegsmund M, Campain J, Gottesman MM, Pastan I. Pseudomonas exotoxin conjugated to monoclonal antibody MRK16 specifically kills multidrug resistant cells in cultured renal carcinomas and in MDR-transgenic mice. J Urol 1993; 149: 174–8.
Merwin JR, Lynch MJ, Madri JA, Pastan I, Siegall CB. Acidic fibroblast growth factor Pseudomonas exotoxin chimeric protein elicits antiangiogenic effects on endothelial cells. Cancer Res 1992; 52: 4995–5001.
Kreitman RJ, Schneider WP Queen C et al. Mik-beta 1(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the beta-chain of the IL-2 receptor. J Immunol 1992; 149: 2810–5.
Godal A, Kumle B, Pihl A, Juell S, Fodstad O. Immunotoxins directed against the high-molecular weight melanoma associated antigen. Identification of potent antibody toxin conjugates. Int J Cancer 1992; 52: 631–5.
Debinski W, Karlsson B, Lindholm L et al. Monoclonal antibody C242 Pseudomonas exotoxin A. A specific and potent immuno-toxin with antitumor activity on a human colon cancer xenograft in nude mice. J Clin Invest 1992; 90: 405–11.
Arom N, Klimpel KR, Singh Y, Leppla SH. Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. J Biol Chem 1992; 267: 15542–8.
Prior TI, Helman LJ, FitzGerald DJ, Pastan I. Cytotoxic activity of a recombinant fusion protein between insulin-like growth factor I and Pseudomonas exotoxin. Cancer Res 1991; 51: 174–80.
Pastan IH, Archer GE, McLendon RE et al. Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. Proc Natl Acad Sci USA 1995; 92: 2765–9.
Hall WA, Myklebust A, Godal A, Nesland JM, Fodstad O. In vivo efficacy of intrathecal transferrin Pseudmonas exotoxin A immu-notoxin against LOX melanoma. Neurosurgery 1994; 34: 649–55.
Kreitman RJ, Chang CN, Hudson DV, Queen C, Bailon P, Pastan I. Anti Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model. Int J Cancer 1994; 57: 856–64.
Leamon CP Pastan I, Low PS. Cytotoxicity of folate Pseudomonas exotoxin conjugates towards tumor cells. Contribution of translocation domain. J Biol Chem 1993; 268:,4847–54.
Lorimer IA, Keppler-Hafkemeyer A, Beers RA, Pegram CN, Bigner DD, Pastan I. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci USA 1996; 93: 14815–20.
Klimka A, Barth S, Drillich S et al. A deletion mutant of Pseudomonas exotoxin-A fused to recombinant human inter-leukin-9 (rhIL-9-ETA') shows specific cytotoxicity against IL-9-receptor-expressing cell lines. Cytokines Mol Ther 1996; 2: 139–46.
Baldwin RL, Kobrin MS, Fran T, Pastan I, Korc M. Cytotoxic effects of TGF-alpha Pseudomonas exotoxin A fusion protein in human pancreatic carcinoma cells. Pancreas 1996; 13: 16–21.
Reiter Y, Wright AF, Tonge DW, Pastan I. Recombinant single-chain and disulfide-stabilized Fv-immumotoxins that cause complete regression of a human colon cancer xenograft in nude mice. Int J Cancer 1996; 67: 113–23.
Pai LH, Wittes R, Setser A, Willingham MC, Pastan I. Treatment of advanced tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nature Med 1996; 2: 350–3.
Benhar I, Pastan I. Characterization of B1(Fv)FE38 and B1(dsFv) PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice. Clin Cancer Res 1995; 1: 1023–9.
Debinski W, Pastan I. Recombinant F(ab') C242 Pseudomonas exotoxin, but not the whole antibody-based immunotoxin, causes regression of a human colorectal tumor xenograft. Clin Cancer Res 1995; 1: 1015–22.
Wolff EA, Hellstrom I, Chace DE Hellstrom KE, Siegall CB. Anti-tumour activity of a melanoma-specific immunotoxin, ME20-LysPE40. Ther Immunol 1995; 2: 137–45.
Francisco JA, Gilliland LK, Stebbins MR, Norris NA, Ledbetter JA, Siegall CB. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen. Cancer Res 1995; 55: 3099–104.
Nechushtan A, Yarkoni S, Marianovsky I, Lorberbaum-Galski H. Adenocarcinoma cells are targeted by the new GnRH-PE66 chi-meric toxin through specific gonadotropin releasing hormone binding sites. J Biol Chem 1997; 272: 11597–603.
Zimmermann S, Wels W, Froesch BA, Gerstmayer B, Stahel RA, Zangemeister-Wittke U. A novel immunotoxin recognizing the epithelial glycoprotein-2 has potent antitumoral activity on chemotherapy-resistant lung cancer. Cancer Immumol Immunother 1997; 44: 1–9.
Fishman A, Lorberbaum-Galski H. Targeted elimination of cells expressing the high-affinity receptor for IgE (Fc) epsilon RI by a Pseudomonas exotoxin-based chimeric protein. Eur J Immunol 1997; 27: 486–94.
Mori T, Shoemaker RH, McMahon JR Gulakowski RJ, Gustafson KR, Boyd MR. Construction and enhanced cytotoxicity of a [cyanovirin-N]-[Pseudomonas exotoxin] conjugate against human immumodeficiency virus-infected cells. Biochem Biophys Res Common 1997; 239: 884–8.
Nishida K, Seto M, Takahashi T et al. In vitro effects of a recombinant toxin, mSCF-PE40, targeting c-kit receptors ectopically expressed in small cell lung cancers. Cancer Lett 1997; 113: 153–8.
Chowdhury PS, Viner JL, Beers R, Pastan I. Isolation by a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci USA 1998; 95: 669–74.
Siegall CB, Bacus SS, Cohen BD et al. HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein. J Biol Chem 1995; 270: 7625–30.
Haggerty HG, Warner WA, Comereski CR et al. BR96sFvPE40 immunotoxin: nonclinical safety assessment. Toxicol Pathol 1999; 27: 87–94.
Kreitman RJ, Wilson WH, White JD et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000; 18: 1622–36.
Rozemuller H, Chowdhury PS, Pastan I, Kreitman RJ. Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated Pseudomonas exotoxin. Int J Cancer 2001; 92: 861–70.
Wang L, Liu B, Schmidt M, Lu Y, Wets W, Fan Z. Antitumor effect of an HER2-specific antibody toxin fusion protein on human prostate cancer cells. Prostate 2001; 47: 21–8.
Bruhl H, Cihak J, Stangassinger M, Schlondorff D, Mack M. Depletion of CCR5-expressing cells with bispecific antibodies and chemokine toxins: a new strategy in the treatment of chronic inflammatory diseases and HIV. J Immunol 2001; 166: 2420–6.
Engebraaten O, Sivam G, Juell S, Fodstad O. Systemic immuno-toxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats. Int J Cancer 2000; 88: 970–6.
Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, Pastan I. Anti-tumor activity of Kl-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother 2000; 23: 473–9.
Barth S, Huhn M, Matthew B et al. Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice. Int J Cancer 2000; 86: 718–24.
Liu S, Netzel-Arnett S, Birkedal-Hansen H, Leppla SH. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res 2000; 60: 6061–7.
Shinohara H, Fan D, Ozawa S et al. Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by anti-transferrin recombinant immuno-toxin. Int J Oncol 2000; 17: 643–51.
Kreitman RJ, Margulies I, Steder-Stevenson M, Wang QC, FitzGerald DJ, Pastan I. Cytotoxic activity of disulfide stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B cell leukemias. Clin Cancer Res 2000; 6: 1476–87.
Proby CM, Ota T, Suzuki H et al. Development of chimeric molecules for recognition and targeting of antigen-specific B cells in pemphigus vulgaris. Br J Dermatol 2000; 142: 321–30.
Bera TK, Viner J, Brinkmanm E, Pastan I. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immuno-toxin with improved antigen binding to erbB2. Cancer Res 1999; 59: 4018–22.
Schmidt M, Maurer-Gebhard M, Groner B, Kohler G, Brochmann-Santas G, Wels W. Suppression of metastasis formation by a recombinant single chain antibody toxin targeted to full-length and oncogenic variant EGF receptors. Oncogene 1999; 18: 1711–21.
Skrepnik N, Zieske AW, Bravo JC, Gillespie AT, Hunt JD. Recombinant oncotoxin AR209 (anti-P185 erbB-2) diminishes human prostate carcinoma xenografts. J Urol 1999; 161: 984–9.
Ben-Yehudah A, Yarkoni S, Nechushtan A, Belostotsky R, Lorberboum-Galski H. Linker-based GnRH-PE chimeric proteins inhibit cancer growth in nude mice. Med Oncol 1999; 16: 38–45.
Klimka A, Barth S, Matthey B et al. An anti-CD30 single chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA) is a potent immunotoxin against a Hodgkin-derived cell line. Br J Cancer 1999; 80: 1214–22.
Seetharam S, Nodzenski E, Beckett MA et al. Modulation of apoptotic response of a radiation-resistant human carcinoma by Pseudomonas exotoxin chimeric protein. Cancer Res 1998; 58: 3215–20.
Akamatsu Y, Murphy JC, Nolan KF et al. A single-chain immuno-toxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells. Clin Cancer Res 1998; 4: 2825–32.
Bera TK, Pastan I. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability. Bioconj Chem 1998; 9: 736–43.
Essand M, Pastan I. Anti-prostate immunotoxins: cytotoxicity of E4 antibody Pseudomonas exotoxin constructs. Intl J Cancer 1998; 77: 123–7.
Yang D, Krum CT, Payner J et al. Recombinant heregulin Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo. Clin Cancer Res 1998; 4: 993–1004.
Mixan B, Cohen BD, Bacus SS, Fell HP, Siegall CB. Betacellulin Pseudomonas toxin fusion proteins bind but are not cytotoxic to cells expressing HER4; correlation of EGFR for cytotoxic activity. Oncogene 1998; 16: 1209–15.
Brenner T, Steinberger I, Soffer D, Beraud E, Ben-Nun A, Lorberboum-Galski H. A novel antigen toxin chimeric protein: myelin basic protein Pseudomonas exotoxin (MBP-PE40) for treatment of experimental autaimmune encephalomyelitis. Immunol Lett 1999; 68: 403–10.
Gregg EO, Bridges SH, Youle RJ et al. Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia. J Immunol 1987; 138: 4502–8.
Boltansky H, Slater J, Youle R, Isersky C, Kalmar M. IgE-immunotoxins. II. IgE-ricin A-chain. Immunopharmacology 1987; 14: 47–62.
Levin IN, Griffin TW, Childs LR, Davis S, Haagensen DE. Comparison of multiple anti-CEA immunotoxins active against human adenocarcinoma cells. Cancer Immunol Immunother 1987; 24: 202–6.
Rennie DP, McGregor AM, Wright J, Weetman AP, Hall R, Thorpe P. An immunotoxin of ricin A chain conjugated to thyro-globulin selectively suppresses the antithyroglobulin autoantibody response. Lancet 1983; 2: 1338–40.
Wiels J, Junqua S, Dujardin P, Le Pecq JR Tursz T. Properties of immunotoxins against a glycolipid antigen associated with Burkitt's lymphoma. Cancer Res 1984; 44: 129–33.
Swam G, Pearson JW, Bohn W, Oldham RK, Sadoff JC, Morgan AC. Immunotoxins to a human melanoma-associated antigen: comparison of geloninwith ricin and other A chain conjugates. Cancer Res 1987; 47: 3169–73.
Street NE, Fulton RJ, Sanders VM, Vitetta ES. Inhibition of helper function of murine T cells with Fab'-anti-L3T4 ricin A chain immunotoxin. J Immunol 1987; 139: 1734–8.
Boltansky H, Dyer J, Esworthy S, Kalmar M. IgE-immunotoxins. I. IgE-intact ricin. Immunopharmacology 1987; 14: 35–45.
Thiesen HJ, Juhl H, Arndt R. Selective killing of human bladder cancer cells by combined treatment with A and B chain ricin antibody conjugates. Cancer Research 1987; 47: 419–23.
Morgan AC, Bordonaro J, Pearson JW, Sivam G. Immunotoxins to a human melanoma-associated antigen: resistance to poke-weed antiviral protein conjugates in vitro. J Natl Cancer Inst 1987; 78: 1101–6.
Uckun FM, Azemove SM, Myers DE, Vallera DA. AntiCD2(T, p50) intact ricin immunotoxins for GVHD-prophylaxis in alloge-neic bone marrow transplantation. Leuk Res 1986; 10: 145–53.
Roth JA, Ames RS, Byers V, Lee HM, Scannon PJ. Monoclonal antibody 45–2D9 conjugated to the A chain of ricin is specifically toxic to c-Ha-ras-transfected NIH 3T3 cells expressing gp74. J Immunol 1986; 136: 2305–10.
Kronke M, Schlick E, Waldmann TA, Vitetta ES, Greene WC. Selective killing of human T-lymphotropic virus-infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody ricin A chain conjugates: potentiation by ammonium chloride and monensin. Cancer Res 1986; 46: 3295–8.
Thorpe PE, Brown AN, Bremner JA, Foxwell BM, Stirpe F. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. J Natl Cancer Inst 1985; 75: 151–9.
Bjorn MJ, Ring D, Frankel AE. Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res 1985; 45: 1214–21.
Preijers FW, de Witte T, Wessels JM et al. Autologous transplantation of bone marrow purged in vitro with antiCD7-(WT1-)ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma. Blood 1989; 74: 1152–8.
Till MA, Zolla-Pazner S, Gorny MK, Patton JS, Uhr JW, Vitetta ES. Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. Proc Nat1 Acad Sci USA 1989; 86: 1987–91.
Byers VS, Rodvien R, Grant K et al. Phase I study of monoclonal antibody ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer. Cancer Res 1989; 49: 6153–60.
Dinota A, Barbieri L, Gobbi M et al. An immunotoxin containing momordin suitable for bone marrow purging in multiple myeloma patients. Br J Cancer 1989; 60: 315 19.
Barbieri L, Dinota A, Gobbi M et al. Immunotoxins containing saporin 6 and monoclonal antibodies recognizing plasma cell-associated antigens: effects on target cells and on normal myeloid precursors (CFU-GM). Eur J Haematol 1989; 42: 238–45.
Conde FP, Orlandi R, Canavan S et al. The Aspergillus toxin restrictocin is a suitable cytotoxic agent for generation of immu-noconjugates with monoclonal antibodies directed against human carcinoma cells. Eur J Biochem 1989; 178: 795–802.
Avila AD, Mateo de Acosta C, Lage A. A new immunotoxin built by linking a hemolytic toxin to a monoclonal antibody specific for immature T lymphocytes. Int J Cancer 1988; 42: 568–71.
Lou Y, Seon BK. Marked difference in the in vivo antitumor effi-cacy between two immunotaxins targeted to different epitopes of common acute lymphoblastic leukemia antigen (CD 10). Mechanisms involved in the differential activities of immunotox-ins. J Immunol 1990; 145: 1974–82.
Colombatti M, Bisconti M, Dell'Arciprete L, Gerosa MA, Tridente G. Sensitivity of human glioma cells to cytotoxic het-eroconjugates. Int J Cancer 1988; 42: 441–8.
Press OW, Martin PJ, Thorpe PE, Vitetta ES. Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells. J Immunol 1988; 141: 4410–7.
Manske JM, Buchsbaum DJ, Hanna DE, Vallera DA. Cytotoxic effects of anti-CD5 radioimmunotoxins on human tumors in vitro and in a nude mouse model. Cancer Res 1988; 48: 7107–14.
Derocq JM, Casellas P, Laurent G, Ravel S, Vidal H, Jansen F. Comparison of the cytotoxic potency of T101 Fab, F(ab)2 and whole IgG immunotoxins. J Immunol 1988; 141: 2837–43.
Preijers FW, Tax WJ, Wessels JM, Capel PJ, De Witte T, Haanen C. Different susceptibilities of normal T cells and T cell lines to immunotoxins. Scand J Immunol 1988; 27: 533–40.
Kanellos J, MacKenzie IF, Pietersz GA. In vivo studies of whole ricin monoclonal antibody immunoconjugates for the treatment of marine tumours. Immunol Cell Rot 1988; 66: 403–15.
Izquierdo M, Balboa MA, Figuera A, Lopez-Botet M. Selective T cell subset depletion with anti-CD4 and antiCD8 intact ricin immunotoxins. Clin Exp Immunol 1988; 74: 300–4.
Shen GL, Li JL, Ghetie MA et al. Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas. Int J Cancer 1988; 42: 792–7.
Cattel L, Delprino L, Brusa P, Dosio F, Comoglio PM, Prat M. Comparison of blocked and non-blocked ricin antibody immuno-toxins against human gastric carcinoma and colorectal adenocarci-noma cell lines. Cancer Immunol Immunother 1988; 27: 233–40.
Ettenson D, Sheldon K, Marks A, Houston LL, Baumal R. Comparison of growth inhibition of a human ovarian adenocarci-noma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins. Anticancer Res 1988; 8: 833–8.
Tazzari PL, Barbieri L, Gobbi M et al. An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and saporin 6: effect on T lymphocytes and hematopoietic cells. Cancer Immunol Immunother 1988; 26: 231–6.
Matsushita S, Koito A, Maeda Y, Hattori T, Takatsuki K. Selective killing of HIV-infected cells by anti-gpl20 immunotoxins. AIDS Res Human Retroviruses 1990; 6: 193–203.
Ghetie V, Till MA, Uhr JW, Vitetta ES. Large scale preparation of an immunoconjugate constructed with human recombinant CD4 and deglycosylated ricin A chain. J Immunol Methods 1990; 126: 135–41.
Engert A, Burrows F, Jung W et al. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease. Cancer Res 1990; 50: 84–8.
Schmidberger, H, King, L, Lasky, LC, Vallera, DA. Antitumor activity of L6 ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo. Cancer Res 1990; 50: 3249–56.
May, RD, Finkelman, FD, Wheeler, HT, Uhr JW, Vitetta, ES. Evaluation of ricin A chain-containing immunotoxins directed against different epitopes on the delta-chain of cell surface-associated IgD on marine B cells. J Immunol 1990; 144: 3637–42.
Wawrzynczak EJ, Derbyshire EI, Henry RV et al. Selective cyto-toxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen. Br J Cancer 1990; 62: 410–4.
Marches R, Mota G, Margineanu M et al. Treatment of murine EL4 leukemia in ascitic form with anti-Thy1.2 specific immuno-toxins. Neoplasma 1990; 37: 573–8.
Wu M, Tang SL, Zang RJ, Yu H. Selective killing of tumor cells in vitro by an immunotoxin composed of ricin and monoclonal antibody against Ia antigen. Int J Immunopharm 1990; 12: 235–9.
Santana, JM, Teixeira, AR. Effect of immumotoxins against Trypanosoma cruzi. Am J Trop Med Hygiene 1989; 41: 177–82.
Shumakov VI, Maisjuk IG, Agapov II et al. In vitro efficacy of conjugates of anti-CD45 monoclonal antibodies with plant toxin A-chains. Transplant Proc 1998; 30: 971–3.
La Russa VF, Griffin JD, Kessler SW et al. Effects of anti-CD33 blocked ricin immumotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. Exp Haematol 1992; 20: 442–8.
Burlet A, Chapleur-Chateau M, Haumont-Pellegri B et al. Longterm reduction of vasopression excretion induced by the central injection of an immunoconjugate (antibody to vasopressin linked to ricin A chain). Neuroscience 1992; 50: 965–73.
Bolognesi A, Tazzari PL, Olivieri F et al. Evaluation of immumo-toxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies. Br J Haematol 1998; 101: 179–88.
Wang QC, Ying WB, Xie H, Zhang ZC, Yang ZH, Ling LQ. Triochsanthin monoclonal antibody conjugate specifically cyto-toxic to human hepatoma cells in vitro. Cancer Res 1991; 51: 3353–5.
Derbyshire PJ, Wawrzynczak EJ. Monoclonal antibodies recognizing the cluster 2 antigen associated with human small cell lung cancer mediate the toxic effects of ricin A chain in an indirect assay of immumotoxin cytotoxicity. Br J Cancer 1991; 14(Suppl): 74–7.
Zong W, Dai B. Preparation of SOKTI-RTA immunotoxin and its specific cytotoxic effect on human T lymphocytes. J West China Univ Med Sci 1991; 22: 240–4.
Engert A, Brown A, Thorpe P. Resistance of myeloid leukemia cell lines to ricin A-chain immumotoxins. Leuk Res 1991; 15: 1079–86.
Rosenblum MG, Murray JL, Cheung L, Rifkin R, Salmon S, Bartholomew R. A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin. Mol Biother 1991; 3: 6–13.
Wawrzynczak EJ, Henry RV, Cumber AJ, Parnell GD, Derbyshire EJ, Ulbrich N. Biochemical, cytodoxic and pharmacokinetic properties of an immunotoxin composed of a mouse monoclonal antibody Fib75 and the ribosome inactivating protein alpha-sarcin from Aspergillus giganteus. Eur J Biochem 1991; 196: 203–9.
Pincus SH, Cole RL, Hersh EM et al. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein. J Immunol 1991; 146: 4315–24.
Shitara K, Hanai N, Kusano A et al. Application of anti-sialyl Lea monoclonal antibody KM231, for immunotherapy of cancer. Anticancer Res 1991; 11: 2003–13.
Ito T, Qiu H, Collins JA, Brill AB, Johnson DK, Griffin TW. Preclinical assessments of 90Y-labeled C110 anti-carcinoembry-onic antigen immumotoxin: a therapeutic immunoconjugate for human colon cancer. Cancer Res 1991; 51: 255–60.
Li S, Zhang XY, Chen XT et al. Targeted anti-tumor agents and their cytotoxicity on gastric cancer cells in vitro. Chinese Med J 1990; 103: 376–9.
Paprocka, M, Wiedlocha, A, Radzikowski, C. Mouse L1210V leukemia as a model to analyse efficiency of leukemic cell elimination by immunotoxin, antibody and complement, and cytostatic agents. In Vivo 1990; 4: 209–13.
Ebert RE, Spryn LA. Immunotoxin construction with a ribosome-inactivating protein from barley. Bioconj Chem 1990; 1: 331–6.
Chiron M, Jaffrezou JP, Carayon P et al. Induction and increase of HLA-DR antigen expression by immune interferon on ML-3 cell line enhances the anti-HLA-DR immunotoxin activity. Clin Exp Immumol 1990; 82: 214–20.
Zenner HP. A monoclonal immunotoxin against laryngeal carcinoma cells. Otolaryngol Polska 1990; 44: 214–5.
Huang YW, Burrows FJ, Vitetta ES. Cytodoxicity of a novel anti-ICAM-1 immunotoxin on human myeloma cell lines. Hybridoma 1993; 12: 661–75.
Duke-Cohan JS, Morimoto C, Schlossman SF. Targeting of an activated T-cell subset using a bispecific antibody toxin conjugate directed against CD4 and CD26. Blood 1993; 82: 2224–34.
Efferth T, Volm M. Modulation of P-glycoprotein-mediated mul-tidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells. Oncology 1993; 50: 303–8.
Zangemeister-Wittke U, Lehmann HP, Waibel R, Wawrzynczak EJ, Stahel RA. Action of a CD24-specific deglycosylated ricin A-chain immumotoxin in conventional and novel models of small-cell-lung-cancer xenograft. Int J Cancer 1993; 53: 521–8.
Calvete JA, Newell DR, Charlton CJ, Wright AF. Pharmacokinetic studies in mice with ICI D0490, a novel recombinant ricin A-chain immumotoxin. Br J Cancer 1993; 67: 1310–5.
Tonevitksy AG, Agapov II, Ershova GV, Sarma T, Toptygin AY, Mechetner EB. Cytodoxic effect of ricin A-chain conjugates containing monoclonal antibodies against human erythroid cells. Int J Immunopharm 1993; 15: 229–35.
Duke-Cohan JS, Morimoto C, Schlossman SF. Depletion of the helper/inducer (memory) T cell subset using a bispecific antibody toxin conjugate directed against CD4 and CD29. Transplantation 1993; 56: 1188–96.
Faguet GB, Agee JF. Four ricin chain A-based immunotoxins directed against the common chronic lymphocytic leukemia antigen: in vitro characterization. Blood 1993; 82: 536–43.
Zangemeister-Wittke U, Collinson AR, Fisch I et al. Antitumor activity of a blocked ricin immunotoxin with specificity against the cluster-5A antigen associated with human small-cell lung cancer. Int J Cancer 1993; 54: 1028–35.
Crews JR, Maier LA, YH et al. A combination of two immuno-toxins exerts synergistic cytodoxic activity against human breast cancer cell liens. Int J Cancer 1992; 51: 772–9.
Tazzari PL, Bolognesi A, de Totero D et al. Ber-H2 (antiCD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. Br J Haematol 1992; 81: 203–11.
Paprocka M, Wiedlocha A, Walzel H, Radzikowski C. The activity of two immunodoxins composed of monoclonal antibody MoAb-16 and A-chain of ricin (MoAb-16-RTA) or A-chain of mistletoe lectin I (MoAb-16-MLIA). Arch Immumol Ther Exp 1992; 40: 223–7.
Derbyshire EJ, Wawrzynczak EJ. An anti-mucin immunotoxin BrE-3-ricin A chain is potently and selectively toxic to human small-cell lung cancer. Int J Cancer 1992; 52: 624–30.
Derbyshire EJ, Stahel RA, Wawrzynczak EJ. Potentiation of a weakly active ricin A chain immumodoxin recognizing the neural cell adhesion molecule. Clin Exp Immunol 1992; 89: 336–40.
Zhao C. Preparation of an anti-human immunotoxin against bladder carcinoma and its in vitro targeting cytotoxicity. Chin J Oncol 1992; 14: 109–11.
Shindo T, Ueda H, Makishima F, Suzuki E, Nishimura H. Efficient selection of mu m-mutants from mu m-expressing myeloma cells by treatment with ricin A-conjugated anti-mu antibody. Somat Cell Mol Genet 1992; 18: 553–8.
Collinson AR, Lambert JM, LiuY et al. Anti-CD6-blocked ricin: an anti-pan T-cell immumotoxin. Int J Immunopharm 1994; 16: 37–49.
Woo BH, Lee IT, Lee KC. Ricin A immumotoxins of IgG and Fab of anti-CALLA monoclonal antibody: effect of water soluble long-chain SPDP on conjugate yield, immunoselectivity and cytotoxicity. Arch Pharm Res 1994; 17: 452–7.
Menzaghi F, Heinrichs SC, Merlo-Pich E, Tilders FJ, Koob GF. Involvement of hypothalamic corticotropin-releasing factor neurons in behavioral responses to novelty in rats. Neurosci Lett 1994; 168: 139–42.
Engert A, Gottstein C, Winkler U et al. Experimental treatment of human Hodgkin's disease with ricin A-chain immumotoxins. Leuk Lymph 1994; 13: 441–8.
Zangemeister-Wittke U, Collinson AR, Frosch B, Waibel R, Schenker T, Stahel RA. Immumotoxins recognizing a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer. Br J Cancer 1994; 69: 32–9.
Deonarain MP, Epenetos AA. Targeting phosphodiesterases as a strategy for killing tumor cells. Cell Biophys 1994; 24: 49–57.
Burrows FJ, Overholser JP, Thorpe PE. Potent antitumor effects of an antitumor endothelial cell immunotoxin in a marine vascular targeting model. Cell Biophys 1994; 24: 15–25.
Goldmacher VS, Bourret LA, Levine BA et al. Anti-CD38 blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood 1994; 84: 301–25.
Tonevitsky AG, Toptygin AI, Agapov II et al. Chimeric toxin of the A-subunit of viscumin and the B-subunit of ricin. Molek Biol 1994; 28: 574–9.
Usui H, Hakomori S. Evaluation of ricin A chain-containing immunotoxins directed against glycolipid and glycoprotein on mouse lymphoma cells. Acta Med Okayama 1994; 48: 305–9.
Thompson PA, McAtee R, Infante AJ, Currier P, Beninati W, Krolick KA. V beta-specific immunotoxin selectively kills ace-tylcholine receptor-reactive T lymphocytes from mice with experimental myasthenia gravis. Int Immunol 1994; 6: 1807–15.
Waurzyniak B, Schneider EA, Tumer N et al. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (antiCD7)-pokeweed antiviral protein immunotoxin. Clin Cancer Res 1997; 3: 881–90.
Zalcberg JR, Pietersz G, Toohey B et al. A phase I/II study of the intralesional injection of ricin monoclonal antibody conjugates in patients with hepatic metastases. Eur J Cancer 1994; 304: 1227–31.
Gottstein C, Schon G, Tawadros S et al. Anti-disialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model. Cancer Res 1994; 54: 6186–93.
Tazzari PL, Bolognesi A, De Totero D et al. Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation. Br J Haematol 1994; 86: 97–105.
Kung AH, Cavagnaro JA, Makin A, White MA, Kong KN. Toxicologic evaluations of an immumotoxin, H65-RTA. Fund Appl Toxicol 1995; 26: 75–84.
Chignola R, Pasti M, Candiani C et al. Escape mechanisms of human leukemic cells to long-term immunotoxin treatment in an in vitro experimental model. Int J Cancer 1995; 61: 535–41.
Lustgarten J, WaksT, Eshhar Z. Prolonged inhibition of IgE production in mice following treatment with an IgE-specific immu-motoxin. Mol Immunol 1996; 33: 245–51.
Lazzaro GE, Meyer BF, Willis JL, Erber WN, Herrmann RP, Davies JM.The synthesis of a peanut agglutinin ricinA chain conjugate: potential as an in vitro purging agent for autologous bone marrow in multiple myeloma. Exp Hematol 1995; 23: 1347–52.
Schnell R, Linnartz C, Katouzi AA et al. Development of new ricin A-chain immumotoxins with potent anti-tumor effects against human Hodkgin cells in vitro and disseminated Hodgkin tumor in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen. Int J Cancer 1995; 63: 238–44.
Conry RM, Khazaeli MB, Saleh MN et al. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration. J Immumother 1995; 18: 231–41.
Lynch TJ, Lambert TM, Coral F et al. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol 1997; 15: 723–34.
Vallera DA, Taylor PA, Panoskaltsis-Mortari A, Blazar BR. Therapy for ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti-CD3 F(ab')2-ricin toxin A chain immunotoxin. Blood 1995; 86: 4367–75.
Chignola R, Anselmi C, Dalla Serra M et al. Self-potentiation of ligand toxin conjugates containing ricin A chain fused with viral structures. J Biol Chem 1995; 270: 23345–51.
Shimizu K, Park KC, Tamura K et al. Internalization with high targeting potential of mouse monoclonal antibody ONS-M21 recognizing human malignant glioma antigen. Cancer Lett 1998; 127: 171–6.
Christiansen SP, Sandnas A, Prill R, Youle RJ, McLoon LK. Acute effects of the skeletal muscle-specific immunotoxin ricin-mAb 35 on extraocular muscles of rabbits. Invest Ophthal Vis Sci 2000; 41: 3402–9.
Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with anti-human endo-glin immunotoxin. Clin Cancer Res 1997; 3: 1031–44.
Wang D, Li Q, Hudson W, Berven E, Uckan F, Kersey JH. Generation and characterization of an anti-CD19 singlechain Fv immunotoxin composed of C-terminal disulfide linked dgRTA. Bioconj Chem 1997; 8: 878–84.
Zewe M, Rybak SM, Dubel S et al. Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnology 1997; 3: 127–36.
Pauza ME, Doumbia SO, Pennell CA. Construction and characterization of human CD7-specific single-chain Fv immunotoxins. J Immunol 1997; 158: 3259–69.
Yoshida M, Rybak RJ, Choi Y et al. Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immumotoxin, and development/application of a clonotype specific polymerase chain reaction-based assay. Cancer Res 1997; 57: 678–85.
Shimizu K, Nagai K, Nakagawa H. An immumotoxin, anti-VIP antibody ricin A chain conjugate eliminates neurons in the hypo-thalamic suprachiasmatic nucleus selectively and abolishes the circadian rhythm of water intake. Brain Res Bull 1996; 41: 369–78.
Barnett BB, Smee DF, Malek SM, Sidwell RW. Selective cyto-toxicity of ricin A chain immunotoxins towards murine cytomeg-alovirus-infected cells. Antimicrob Agents Chemother 1996; 40: 470–2.
Surolia N, Misquith S. Cell surface receptor directed targeting of toxin to human malaria parasite, Plasmodium falciparum. FEBS Lett 1996; 396: 57–61.
Dore JM, Gras F, Wijdenes J. Expression and activity of a recombinant chimeric protein composed of pokeweed antiviral protein and of human interleukin-2. FEBS Lett 1997; 402: 50–2.
Scott CF, Goldmacher VS, Lambert JM, Jackson JV, McIntyre GD. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors. J Natl Cancer Inst 1987; 79: 1163–72.
Longo DL, Duffey PL, Gribben JG et al. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study. Cancer J Sci Am 2000; 6: 146–50.
Tazzari PL, de Totern D, Bolognesi A et al. An Epstein Barr virus-infected lymphoblastoid cell line (3430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotox-ins. Haematologica 1999; 84: 988–95.
Sharma S, Podder SK, Karande AA. Comparative studies on kinetics of inhibition of protein synthesis in intact cells by ricin and a conjugate of ricin B-chain with momordin. Mol Cell Biochem 1999; 200: 133–41.
Matsuno F, Haratu Y, Kondo M, Tsai H, Barcos M, Seon BK. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999; 5: 371–82.
Ohtomo T, Kawata H, Sekimori Y et al. A humanized single-chain Fv fragment with high targeting potential against human malignant gliomas. Anticancer Res 1998; 18: 4311–5.
Clinchy B, Vitetta ES. The use of an anti-CD3 immunotaxin to prevent the development of lymphoproliferative disease in SCID/ PBL mice. J Immunol Meth 1998; 218: 141–53.
Ippoliti R, Ginobbi P, Lendaro F et al. The effect of monensin and chlunquine on the endocytosis and toxicity of chimeric toxins. Cell Mol Life Sci 1998; 54: 866–75.
Boyer CM, Pusztai L, Wiener JR et al. Relative cytodoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer 1999; 82: 525–31.
Weinberg AD, Bourdette DN, Sullivan TJ et al. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmume encephalomyelitis. Nature Med 1996; 2: 183–98.
Casellas P, Brown JP, Gros O et al. Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma-associated antigen p97. Int J Cancer 1982; 30: 437–43.
Masui H, Kamrath H, Apell G, Houston LL, Mendelsohn J. Cytodoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res 1989; 49: 3482–8.
Rybak SM, Saxena SK, Ackerman EJ, Youle RJ. Cytodoxic potential of ribonuclease and ribonuclease hybrid proteins. J Biol Chem 1991; 266: 21202–7.
Frankel AE, Laver JH, Willingham MC, Burns LI, Kersey JH, Vallera DA. Therapy of patients with T-cell lymphomas and leu-kemias using an anti-CD7 monoclonal antibody ricin A chain immunotoxin. Leuk Lymph 1997; 26: 287–98.
Terenzi A, Bolognesi A, Pasqualucci L et al. Anti-CD30 (BERH2) immunotoxins containing the type-1 ribosome inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. Br J Haematol 1996; 92: 872–9.
Battalli MG, Polito L, Bolognesi A, Lafleur L, Fradet Y, Stirpe F. Toxicity of ribosome-inactivating proteins containing immuno-toxins to a human bladder carcinoma cell line. Int J Cancer 1996; 65: 485–90.
Myers DE, Uckun FM. An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia. Leuk Lymph 1995; 18: 119–22.
Smith CV, Sablinski T, Arn JS et al. In vivo treatment with monoclonal antibodies directed against CD4 and CD8 antigens in miniature swine. J Immunother 1994; 16: 105–14.
Ek O, Gaynon P, Zeren T, Chelstrom LM, Myers DE, Uckun FM. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methyl-prednisolone, and L-asparaginase. Leuk Lymph 1998; 31: 143–9.
Kwok KH, Law KB, Wong RN, Yung KK. Immunolesioning of nerve growth factor p75 receptor-containing neurons in the rat brain by a novel immunotoxin: anti-p75-anti-mouse IgG-trichosanthin conjugates. Brain Res 1999; 846: 154–63.
Flavell DJ, Boehm DA, Noss A, Warnes SL, Flavell SU. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38 saporin immunotoxins is significantly better than therapy with each individual immunotoxin. Br J Cancer 2001; 84: 571–8.
Davol P, Beitz JG, Mohle, M et al. Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model. Cancer 1995; 76: 79–85.
Maciejewski-Lenoir D, Heinrichs SC, Liu XJ et al. Selective impairment of corticotropin-releasing factor 1 (CRF1) receptor-mediated function using CRF coupled to saporin. Endocrinology 2000; 141: 498–504.
Chandler LA, Sosnowski BA, McDonald JR et al. Targeting tumor cells via EGF receptors: selective toxicity of an HBEGF-toxin fusion protein. Int J Cancer 1998; 78: 106–11.
Ippoliti R, Lendaro E, Bellelli A et al. A saporin-insulin conjugate: synthesis and biochemical characterization. Nat Toxins 1996; 4: 156–62.
Vooijs WC, Post J, Wijdenes J et al. Efficacy and toxicity of plasma cell reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins. Cancer Immunol Immunother 1996; 42: 319–28.
Dosio F, Brusa P, Crosasso P, Fruttero C, Cattel L, Bolognesi A. Synthesis of different immunotaxins composed by ribosome inactivating proteins non-covalendy bound to monoclonal antibody. Farmaco 1996; 51: 477–82.
Flavell DJ, Flavell SU, Boehm DA et al. Preclinical studies with the anti-CD19 saporin immunotoxin BU12-saporin for the treatment of human B cell tumours. Br J Cancer 1995; 72: 1373–9.
Cazzola M, Bergamaschi G, Dezza L et al. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors. Cancer Res 1991; 51: 536–41.
Blank M, Manosroi J, Tamer Y et al. Suppression of experimental systemic erythematosus (SLE) with specific anti-idiotypic antibody saporin conjugate. Clin Exp Immunol 1994; 98: 434–41.
Tecce R, Digiesi G, Savarese A, Trizio D, Natali PG. Characterization of cytotoxic activity of saporin antigp185/HER-2 immunotoxins. Int J Cancer 1993; 55: 122–7.
Bonardi MA, French RR, Amlot P, Gromo G, Modena D, Glennie MJ. Delivery of saporin to human B-cell lymphoma using bispe-cific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing. Cancer Res 1993; 53: 3015–21.
Poccia F, Piselli P, Di Cesare S et al. Recognition and killing of tumour cells expressing heat shock protein 65 kD with immuno-toxins containing saporin. Br J Cancer 1992; 66: 427–32.
Tazzari PL, Bolognesi A, De Totero D et al. B-B10 (antiCD25)-saporin immunotoxin a possible tool in graft versus host disease treatment. Transplant 1992; 54: 351–6.
Tecce R, Nicotra MR, Fraioli R, Cuomo M, Trizio D, Natali PG. Saporin 6 conjugated to monoclonal antibody selectively kills human melanoma cells. Melanoma Res 1991; 1: 115–23.
Tecce R, Fraioli R, De Frabritiis P et al. Production and characterization of two immunotoxins specific for M5b ANLL leukaemia. Int J Cancer 1991; 49: 310–6.
Dinota A, Tazzari PL, Michieli M et al. In vitro bone marrow purging of muftidrug resistant cells with a mouse monoclonal antibody directed against M, 170,000 glycoprotein and a saporin-conjugated anti-mouse antibody. Cancer Res 1990; 50: 4291–4.
Siena S, Bragni M, Formosa A al. Immunotoxin mediated killing of clonable T-lymphocytes infiltrating an irreversibly rejected human renal allograft. J Biol Resp Reg Homeostatic Agents 1989; 3: 84–8.
Bragni M, Siena S, Formosa A et al. B-cell restricted saporin immunotoxins: activity against b-cell lines and chronic lympho-cytic leukemia cells. Blood 1989; 73: 753–62.
Barbieri L, Bolognesi A, Dinota A et al. Selective killing of CD4+ and CD8+ cells with immunotoxins containing saporin. Scand J Immunol 1989; 30: 369–72.
Barbieri L, Dinota A, Gobbi M et al. Immuntoxins containing saporin 6 and monoclonal antibodies recognizing plasma cell-associated antigens: effects on target cells and on normal myeloid precursors (CFU-GM). Eur J Haematol 1989; 42: 238–45.
Bragni M, Lappi DA, Siena, S et al. Activity of a monoclonal antibody saporin 6 conjugate against B-lymphoma cells. J Natl Cancer Inst 1988; 80: 511–7.
Glennie MJ, McBride HM, Stirpe F, Thorpe PE, Worth AT, Stevenson GT. Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of anti-idiotypic antibody and saporin. J Exp Med 1987; 166: 43–62.
Singh V, Curtiss R. Hormonotoxins: the role of positive charge of lysine residue on the immunological, biological, and cytotoxic properties of ovine lutropin-S-S-gelonin conjugates. Mol Cell Biochem 1994; 130: 91–101.
Scott CF, Goldmacher VS, Lambert JM et al. The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome inactivating protein gelonin. Cancer Immunol Immunother 1987; 25: 31–40.
Wenning LA, Murphy RM. Coupled cellular trafficking and dif-fusional limitations in delivery of immunotoxins to multicell tumor spheroids. Biotech Bioeng 1999; 62: 562–75.
Pagliaro LC, Liu B, Munker R et al. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. Clin Cancer Res 1998; 4: 1971–6.
Arpicco S, Dosio F, Brusa P, Crosasso P, Cattel L. New coupling reagents for the preparation of disulfide-linked conjugates with increased stability. Bioconj Chem 1997; 8: 327–37.
Smee DF, Sidwell RW, Barnett BB. Combination of antiviral immu-notoxin and ganciclovir or cidofovir for the treatment of murine cytomegalovirus infections. Antiviral Res 1996; 32: 165–71.
O'Boyle KP, Colletti D, Mazurek C et al. Potentiation of antipro-liferative effects of monoclonal antibody Lym-1 and immuno-conjugate Lym-1-gelonin on human Burkitt's lymphoma cells with gamma-interferon and tumor necrosis factor. J Immunother 1995; 18: 221–30.
Barnett BB, Smee DF, Malek SM, Sidwell RW. Selective cyto-toxicity towards cytomegalovirus-infected cells by immunotox-ins consisting of gelonin linked to anti-cytomegalovirus antibody. Antiviral Res 1995; 28: 93–100.
Misquith S, Surolia A. In vivo treatment of Heymann's nephritis using a cytotoxic protein toxin conjugate. FEBS Lett 1995; 373: 151–4.
Masuda K, Takahashi K, Nagata S, Hirano K, Takagishi Y. Immunotoxins composed of monoclonal antibody to alphafeto-protein and gelonin as a potent hepatoma-targeted drug delivery system. J Drug Targeting 1994; 2: 323–31.
Rosenblum MG, Zuckerman JE, Marks JW, Rotbein J, Allen WR. A gelonin-containing immunotoxin directed against human breast carcinoma. Mol Biother 1992; 4: 122–9.
Barnett BB, Burns NJ, Park KJ, Dawson MI, Kende M, Sidwell RW. Antiviral immunotoxins: antibody-mediated delivery of gelonin inhibits Pichinde virus replication in vitro. Antiviral Res 1991; 15: 125–38.
Harris P, Reed E, King DW, Suciu-Foca N. In vitro studies of the effect of Mab NDA4 linked to toxin on the proliferation of a human EBV-transformed lymphoblastoid B cell line and of gibbon MLA leukemia cell line. Cell Immunol 1991; 134: 85–95.
Mujoo K, Reisfeld RA, Cheung L, Rosenblum MG. A potent and specific immunotoxin for tumor cells expressing disialoganglio-side GD2. Cancer Immunol Immunother 1991; 34: 198–204.
Cumber AJ, Henry RV, Parnell GD, Wawrzynczak EJ. Purification of immunotoxins containing the ribosome inactivating proteins gelonin and momordin using high performance liquid immunoaf-finity chromatography compared with blue sepharose CL-6B affinity chromatography. J Immunol Meth 1990; 135: 15–24.
Hirota N, Ueda M, Ozawa S, Abe O, Shimizu N. Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. Cancer Res 1989; 49: 7106–9.
Reimann KA, Goldmacher VS, Lambert JM et al. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. IV. Cytotoxic effect of an antiT11-gelonin immuno-toxin. J Clin Invest 1988; 82: 129–38.
Tedder TF, Goldmacher VS, Lambert JM, Schlossman SF. Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system. J Immunol 1986; 137: 1387–91.
Colombatti M, Bron C. Sensitivity of target cells to immunotox-ins: possible role of cell-surface antigens. Immunology 1985; 55: 331–8.
Psarras K, Ueda M, Tanabe M et al. Targeting activated lymphocytes with an entirely human immunotoxin analogue: human pancreatic RNasel-human IL-2 fusion. Cytokine 2000; 12: 786–90.
Yoon JM, Han SH, Kown OB Kim SH, Park MH, Kim BK. Cloning and cytotoxicity of fusion proteins of EGF and angio-genin. Life Sci 1999; 64: 1435–45.
Frankel AE, Ramage J, Latimer A et al. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for phase I clinical trials. Prot Expres Purif 1999; 16: 190–201.
Hotchkiss CE, Hall PD, Cline JM et al. Toxicology and pharma-cokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte macrophage colony-stimulating factor, in cynomolgas monkeys. Toxicol Appl Pharm 1999; 158: 152–60.
Feuring-Buske M, Buske C, Unterhalt M, Hiddemann W. Recent advances in antigen-targeted therapy in non-Hodkgin's lymphoma. Ann Hematol 2000; 79: 167–74.
Kreitman RJ, Wilson WH, Bergeron K et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345: 241–7.
Kreitman RJ, Wilson WH, Robbins D et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood 1999; 94: 3340–8.
Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin Tf-CRM107 in patients with malignant brain tumors. Nature Med 1997; 3: 1362–8.
Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003; 65: 3–13.
LeMaistre CF, Saleh MN, Kuzel TM et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998; 91: 399–405.
Olsen E, Duvic M, Frankel A et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376–88.
Foss F, Demierre MF, DiVenuti G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005; 106: 454–7.
Duvic M, Cather J, Maize J, Frankel AE. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Am J Hematol 1998; 58: 87–90.
Saleh MN, LeMaistre CF, Kuzel TM et al. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998; 39: 63–73.
Talpur R, Apisarnthanarax N, Ward S, Duvic M. Treatment of relapsed refractory peripheral T-cell lymphoma with denileukin diftitox (Ontak): a case report of one patient. Leuk Lymph 2002; 43: 121–6.
Gottlieb SL, Gilleaudeau P, Johnson R et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995; 1: 442–7.
Gottlieb AB, Bacha P, Parker K, Strand V. Use of the interleu-kin-2 (IL-2) fusion protein, DAB389IL-2, for the treatment of psoriasis. Dermatol Ther 1998; 5: 48–63.
Bagel J, Garland WT, Breneman D et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol 1998; 38: 938–44.
Uckun FM. Immunotoxins for the treatment of leukaemia. Br J Haematol 1993; 85: 435–8.
Sausville EA, Headlee D, Stetler-Stevenson M et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. Blood 1995; 85: 3457–65.
Senderowicz AM, Vitetta F, Headlee D et al. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann Intern Med 1997; 126: 882–5.
Amlot PL, Stone MJ, Cunningham D et al. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of b-cell lymphomas resistant to conventional therapy. Blood 1993; 82: 2624–33.
Vitetta ES, Stone M, Amlot P et al. Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 1991; 51: 4052–8.
Falini B, Bolognesi A, Flenghi L et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 1992; 339: 1195–6.
Goldberg MR, Heimbrook DC, Russo P et al. Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin Cancer Res 1995; 1: 57–61.
Tepler I, Schwartz G, Parker K et al. Phase I trial of an interleu-kin-2 fusion toxin (DAB4861L-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 1994; 73: 1276–85.
Platanias, LC, Ratain, MJ, O'Brien, S, Larson, RA, Vardiman, JW, Shaw, JP, Williams, SF, Baron, JM, Parker, K, Woodworth, TG. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486L-2) as a 6 h intravenous infusion in patients with hematologic malignancies. Leuk Lymph 1994; 14: 257–62.
LeMaistre CF, Craig FE, Meneghetti C et al. Phase I trial of a 90 minute infusion of the fusion toxin DAB486IL-2 in hematological cancers. Cancer Res 1993; 53: 3930–4.
LeMaistre CF, Meneghetti C, Rosenblum M et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hemato-logic malignancies expressing the IL-2 receptor. Blood 1992; 79: 2547–54.
LeMaistre CF, Rosenblum MG, Reuben JM et al. Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia. Lancet 1991; 337: 1124–5.
Hesketh P, Caguioa P, Koh H et al. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J Clin Oncol 1993; 11: 1682–90.
vanderSpek J, Cosenza L, Woodworth T, Nichols JC, Murphy JR. Diphtheria toxin-related cytokine fusion proteins: elongation factor 2 as a target for the treatment of neoplastic disease. Mol Cell Biochem 1994; 138: 151–6.
Foss FM, Borkowski TA, Gilliom M et al. Chimeric fusion protein toxin DAB4861L-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 1994; 84: 1765–74.
Sewell KL, Parker KC, Woodworth TG, Reuben J, Swartz W, Trentham DE. DAB486IL-2 fusion toxin in refractory rheumatoid arthritis. Arthritis Rheum 1993; 9: 1223–33.
Moreland LW, Sewell KL, Trentham DE et al. Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. Arthritis Rheum 1995; 9: 1177–86.
Schrohenloher RE, Koopman WJ, Woodworth TG, Moreland LW. Suppression of in vitro IgM rheumatoid factor production by diphtheria toxin interleukin 2 recombinant fusion protein (DAB486IL-2) in patients with refractory rheumatoid arthritis. J Rheumatol 1996; 23: 1845–8.
LeMaistre CF, Rosen S, Frankel A et al. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous Tcell lymphoma. Blood 1991; 78: 1173–82.
Stone MJ, Sausville EA, Fay JW et al. A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 1996; 88: 1188–97.
Messman RA, Vitetta ES, Headlee D et al. A phase I study of combination therapy with immunotoxins IgG-HD37deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD 19(+), CD22(+) B cell lymphoma. Clin Cancer Res 2000; 6: 1302–13.
Grossbard ML, Freedman AS, Ritz J et al. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 1992; 79: 576–85.
Grossbard ML, Lambert JM, Goldmacher VS et al. AntiB4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 1993; 11: 726–37.
Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK. Intratumoral administration of recombinant circularly permuted interleukin-4 Pseudomonas exotoxin in patients with highgrade glioma. Clin Cancer Res 2000; 6: 2157–65.
LeMaistre CF, Deisseroth A, Foget B et al. Phase I trial of H65-RTA in patients with chronic lymphocytic leukemia. Blood 1990; 76(Suppl. 1): 295a.
Weiner LM, O'Dwyer J, Kitson J et al. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9 recombinant ricin A chain immunoconjuate. Cancer Res 1989; 49: 4062–7.
Spitler LE, del Rio M, Khentigan A et al. Therapy of patients with malignant melanoma using a monoclonal anti-melanoma antibody-ricin A chain immunotoxin. Cancer Res 1987; 47: 1717–23.
Oratz R, Speyer JL, Wernz JC et al. Antimelanoma monoclonal antibody ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial. J Biol Resp Mod 1990; 9: 345–54.
Spitler L, Mishak R, Scannon P. Therapy of metastatic melanoma with Xomazyme Mel, a murine monoclonal antibody ricin A chain immunotoxin. Int J Rad Appl Instrum [B] 1989; 16: 625–7.
Waldman T, Pastan I, Gansow O, Junghans R. The multichain interleukin-2 receptor: a target for immunotherapy. Ann Intern Med 1992; 116: 148–60.
Bookman MA, Godfrey S, Padavic K et al. Anti-transferrin receptor immunotoxin (IT) therapy: phase I intraperitoneal (i.p) trial. Proc Am Soc Clin Oncol 1990; 9: 187.
Laske DW, Muraszko KM, Oldfield EH et al. Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery 1997; 41: 1039–51.
LynchTJ, Lambert JM, Coral F et al. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol 1997; 15: 723–34.
Pai-Scherf LH, Villa J, Pearson D, Watson T, Liu E, Willingham MC, Pastan I. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin Cancer Res 1999; 5: 2311–5.
van Oosterhout YVJM, van Emst L, Schattenberg AVMB et al. A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease. Blood 2000; 95: 3693–701.
Engert A, Diehl V, Schnell R et al. A phase I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 1997; 89: 403–10.
Postan. I, Hassam R, Fitzgerald DJ et al. Immunotoxin therapy of cancer. Nature Rev. Cancer 2006; 6; 559–565.
Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 2002; 8: 1004–13.
Theodoulou M, Baselga J, Scher H et al. Phase I doseescalation study of the safety, tolerability, pharmacokinetics and biologic effects of DAB389EGF in patients with solid malignancies that express EGF receptors (EGFr). Proc Am Soc Clin Oncol 1995; 14: 480.
Byers VS, Henslee PJ, Kernan NA et al. Use of an anti-pan T-lymphocyte ricin A chain immunotoxin in steroid-resistant acute graft-versus-host disease. Blood 1990; 75: 1426–32.
Martin PJ, Nelson BJ, Appelbaum FR et al. Evaluation of an CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1996; 88: 824–30.
Grossbard ML, Mullion PS, Freedman AS et al. A phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodkgin's lymphoma. Clin Cancer Res 1999; 5: 2392–8.
Multani PS, O'Day S, Nadler LM, Grossbard ML. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Clin Cancer Res 1998; 4: 2599–604.
Scadden DT, Schenkein DP, Bernstein Z et al. Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma. Cancer 1998; 83: 2580–7.
Grossbard ML, Fidias P, Kinsella I et al. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma. Br J Haematol 1998; 102: 509–15.
Piascik P. FDA approves fusion protein for treatment of lymphoma. J Am Pharm Assoc 1999; 39: 571–2.
Hall PD, Virella G, Willoughby T, Atchley DH, Kreitman RJ, Frankel AE. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte macrophage colony-stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myel-oid leukemia. Clin Immunol 2001; 100: 191–7.
Rose DM, Pai LH, Pastan I. Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins. Eur J Immunol 1997; 27: 1459–68.
Hertler AA, Spitler LE, Frankel AE. Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma. Cancer Drug Delivery 1987; 4: 245–53.
Onda M, Nagata S, Tsutsumi Y et al. Lowering the isoelectric point of the Fv portion of the recombinant immunotoxins leads to decreased non-specific animal toxicity without affecting antitumor activity. Cancer Research 2001; 61: 5070–7.
Onda M, Willingham MC, Wang QC et al. Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)PE38, LMB-2. J Immunol 2000; 165: 7150–6.
Baluna R, Coleman F, Jones C, Ghetie V, Vitetta FS. The effect of a monoclonal antibody coupled to ricin A chain derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp Cell Res 2000; 258: 417–24.
Siegall CB, Liggitt D, Chace D et al. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. Clin Cancer Res 1997; 3: 339–45.
Kaneta Y, Tsukazaki K, Kubushiro K et al. Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endome-trial adenocarcinoma on antigen-producing tumor cells in vivo. Jpn J Cancer Res 1998; 89: 583–8.
Singh R, Browning JL, Abi-Habib R et al. Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anticancer Drugs 2007; 18: 809–16.
Williams SA, Merchant RF, Garrett-Mayer E et al. A prostate-specific antigen-activated channel-forming toxin as therapy for prostate disease. J Natl Cancer Inst 2007; 99: 376–85.
Su Y, Ortiz J, Liu S et al. Systemic urokinase-activated anthrax toxin therapy produces regressions of subcutaneous human non-small cell lung tumor in athymic nude mice. Cancer Res 2007; 67: 3329–36.
Stish BJ, Oh S, Vallera DA. Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model. J Neurooncol 2007; Dec 15 Epub.
Stish BJ, Chen H, Shu Y et al. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 2007; 13: 3058–67.
Rustamzadeh E, Vallera DA, Todhunter DA et al. Immunotoxin pharmacokinetics: a comparison of the anti-glioblastoma bispe-cific fusion protein (DTAT13) to DTAT and DTIL13. J Neurooncol 2006; 77: 257–66.
Vallera DA, Todhunter DA, Kuroki DW et al. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lym-phoma. Clin Cancer Res 2005; 11: 3879–88.
Abi-Habib RJ, Liu S, Bugge TH et al. A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-mac-rophage colony-stimulating factor receptor is selectively cyto-toxic to human acute myeloid leukemia blasts. Blood 2004; 104: 2143–8.
Stish BJ, Chen H, Shu Y et al. A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer. Clin Cancer Res 2007; 13: 6486–93.
Avia AD, Calderon CF, Perez RM et al. Construction of an immu-notoxin by linking a monoclonal antibody against the human epidermal growth factor receptor and a hemolytic toxin. Biol Res 2007; 40: 173–183.
Benitez J, Ferreras JM, Munoz R et al. Cytotoxicity of an ebulin I-anti-human CD105 immunotoxin on mouse fibroblasts (L929) and rat myoblasts (L6E9) cells expressing human CD105. Med Chem 2005; 1: 65–70.
Cohen S, Cahan R, Ben-Dov E et al. Specific targeting to murine myeloma cells of Cyt1Aa toxin from Bacillus thuringiensis spub-species israelensis. J Biol Chem 2007; 282: 28301–8.
Foster KA, Adams EJ, Durose L et al. Re-engineering the target specificity of Clostridial neurotoxins-a route to novel therapeutics. Neurotox Res 2006; 9: 101–7.
Jia Y, Li H, Chen W, Li M et al. Prevention of murine autoimmune encephalomyelitis by in vivo expression of a novel recombinant immunotoxin DT390-RANTES. Gene Ther 2006; 13: 1351–9.
Bang SH, Nagata S, Onda M et al. HA22(R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005; 11: 1545–50.
Marks AJ, Cooper MS, Anderson RJ et al. Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide. Cancer Res 2005; 65: 2373–7.
Pincus SH, Fang H, Wilkinson RA et al. In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection. J Immunol 2003; 170: 2236–41.
Stocker M, Tur MK, Sasse S et al. Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of trans-fected 293T-cells. Protein Expr Purif 2003; 28: 211–9.
van Roon JA, van Vuuren AJ, Wijngaarden S et al. Selective elimination of synovial inflammatory macrophages in rheumatoid arthritis by an Fcgamma receptor 1-directed immunotoxin. Arthritis Rheum 2003; 48: 1229–38.
Shin YK, Choi YL, Choi EY et al. Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemia cell line and its clinical implications. Cancer Immunol Immunother 2003; 52: 506–12.
Di Paolo C, Willuda J, Kubetzko S et al. A recombinant immuno-toxin derived from a humanized epithelial cell adhesion mole-cule-specific single-chain antibody fragment has potent and selective anti-tumor activity. Clin Cancer Res 2003; 9: 2837–48.
Rosenblum MG, Cheung LH, Liu Y et al. Design, expression, purification, and characterization, in vitro and in vivo, of an anti-melanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res 2003; 63: 3995–4002.
Otten HG, de Gast GC, Vooijs WC et al. Preclinical evaluation of anti-CD86 immunotoxin in rhesus monkeys: analysis of systemic toxicity, pharmacokinetics, and effect on primary T-cell responses. Cancer Immunol Immunother 2003; 52: 569–75.
Xia HC, Li F, Zhang ZC. Purification and characterization of Moschatin, a novel type I ribosome-inactivating protein from the mature seeds of pumpkin (Cucurbita moschata) and preparation of its immunotoxin against human melanoma cells. Cell Res 2003; 13: 369–74.
Zhang RP, Xiong CY, Yan M, Zhang ZC. In vitro inhibition of human melanoma cells by immunotoxin luffin B-Ng76. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 1998; 30: 561–4.
Tur MK, Huhn M, Thepen T et al. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Res 2003; 63: 8414–9.
Liu Y, Cheung LH, Marks JW et al. Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor. Int J Cancer 2004; 108: 549–57.
Palmisano GL, Tazzari PL, Cozzi E et al. Expression of CTLA-4 in non-human primate lymphocytes and its use as a potential target for specific immunotoxin-mediated apoptosis: results of in vitro studies. Clin Exp Immunol 2004; 135: 259–66.
Wan L, Zeng L, Chen L et al. Expression, purification, and refolding of a novel immunotoxin containing humanized single-chain fragment variable antibody against CTLA4 and the N-terminal fragment of human perforin. Protein Expr Purif 2006; 48: 307–13.
Onda M, Wang QC, Guo HF et al. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma and neuroblastoma. Cancer Res 2004; 64: 1419–24.
Saavedra-Lozano J, Cao Y, Callison J et al. An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on HAART with little effect on CD8 memory. Proc Natl Acad Sci USA 2004; 101: 2494–9.
Martsev SP, Tsybovsky YI, Stremovskiy OA et al. Fusion of the anti-ferritin antibody VL domain to barnase results in enhanced solubility and altered pH stability. Protein Eng Des Sel 2004; 17: 85–93.
Kurschus FC, Kleinschmidt M, Fellows E et al. Killing of target cells by redirected granzyme B in the absence of perforin. FEBS Lett 2004; 562: 87–92.
Polito L, Bolognesi A, Tazzari PL et al. the conjugate Rituximab/ saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine. Leukemia 2004; 18: 1215–22.
De Lorenzo C, Arciello A, Cozzolino R et al. A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. Cancer Res 2004; 64: 4870–4.
Huang X, Bennett M, Thorpe PE. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate 2004; 61: 1–11.
Bruell D, Bruns CJ, Yezhelyev M et al. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. Int J Mol Med 2005; 15: 305–13.
Li H, Li MY, Jiang ZH et al. Construction and prokaryotic expression of a recombinant immunotoxin fused with mouse interleukin 18 and truncated Pseudomonas exotoxin. Sichuan Da Xue Xue Bao Yi Xue Ban 2004; 35: 753–6.
Arditti FD, Rabinkov A, Miron T et al. Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-allinase conjugate. Mol Cancer Ther 2005; 4: 325–31.
Cui JX, Ji JF, Lv AG et al. Construction and expression of novel immunotoxin cpIL-4 (13D)-PE38KDEL with increased activity. Biochemistry 2005; 70: 62–8.
Erickson HA, Jund MD, Pennell CA. Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition. Protein Eng Des Sel 2006; 19: 37–45.
Foehr ED, Lorente G, Kuo J et al. Targeting of the receptor protein tyrosine phosphatase β with a monoclonal antibody delays tumor growth in a glioblastoma model. Cancer Res 2006; 66: 2271–8.
Bremer E, Samplonius DF, Peipp M et al. Target cell-restricted apop-tosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res 2005; 65: 3380–8.
Chang CH, Sapra P, Vanama SS et al. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/ anti-CD74 humanized IgG4 antibody immunotoxin. Blood 2005; 106: 4308–14.
Nagai T, Tanaka M, Tsuneyoshi Y et al. In vitro and in vivo effi-cacy of a recombinant immunotoxin against folate receptor beta on the activation and proliferation of rheumatoid arthritis synovial cells. Arthritis Rheum 2006; 54: 3126–34.
Stocker M, Klockenbring T, Huhn M et al. Antigen-specific targeting and elimination of EBV-transformed B cells by allergen toxins. J Allergy Clin Immunol 2005; 116: 910–5.
Hossann M, Li Z, Shi Y et al. Novel immunotoxin: a fusion protein consisting of gelonin and an acetylcholine receptor fragment as a potential immunotherapeutic agent for the treatment of Myasthenia gravis. Protein Expr Purif 2006; 46: 73–84.
Wolf P, Gierschner D, Buhler P et al. A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxic-ity against prostate cancer cells. Cancer Immunol Immunother 2006; 55: 1367–73.
Bolognesi A, Polito L, Farini V et al. CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia. J Biol Regul Homeost Agents 2005; 19: 145–52.
Schwemmlein M, Peipp M, Barbin K et al. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells. Br J Haematol 2006; 133: 141–51.
van Vuuren AJ, van Roon JA, Walraven V et al. CD64-directed immunotoxin inhibits arthritis in a novel CD64 transgenic rat model. J Immunol 2006; 176: 5833–8.
Zhang H, Zhang S, Zhang H et al. Cytotoxicity of a novel fibro-blast growth factor receptor targeted immunotoxin on a human ovarian teratocarcinoma cell line. Cancer Biother Radiopharm 2006; 21: 321–32.
Fuchs H, Bachran C, Li T et al. A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice. J Control Release 2007; 117: 342–50.
Hess PR, Barnes C, Woolard MD et al. Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin. Blood 2007; 109: 3300–7.
Xi Y, Yuan Z, Zhang H et al. Molecular construction and characterization of a novel exotoxin fusion protein that selectively blocks the B7:CD28 costimulatory signal system. J Immunother 2006; 29: 586–95.
Singh R, Samant U, Hyland S et al. Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors. Mol Cancer Ther 2007; 6: 562–9.
Chen W, Li H, Jia Y et al. In vivo administration of plasmid DNA encoding recombinant immunotoxin DT390-IP-10 attenuates experimental autoimmune encephalomyelitis. J Autoimmun 2007; 28: 30–40.
Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother 2007; 30: 607–13.
Baatar D, Olkhanud P, Newton D et al. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors. J Immunol 2007; 179: 1996–2004.
Munoz R, Arias Y, Ferreras JM et al. Targeting a marker of the tumour neovasculature using a novel anti-human CD105-immunotoxin containing the non-toxic type 2 ribosome-inacti-vating protein nigrin b. Cancer Lett 2007; 256: 73–80.
Ochiai H, Archer GE, Herndon JE et al. EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. Cancer Immunol Immunother 2008; 57: 115–21.
Braschoss S, Hirsch B, Dubel S et al. New anti-CD30 human pancreatic ribonuclease-based immunotoxin reveals strong and specific cytotoxicity in vivo. Leuk Lymphoma 2007; 48: 1179–86.
Bak S P, Walters JJ, Takeya M et al. Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression. Cancer Res 2007; 67: 4783–9.
Schwemmlein M, Stieglmaier J, Kellner C et al. A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells. Leukemia 2007; 21: 1405–12.
Wang H, Song S, Kou G et al. Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome. Cancer Immunol Immunother 2007; 56: 1775–83.
Kim GB, Wang Z, Liu YY et al. A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxin. Protein Eng Des Sel 2007; 20: 425–32.
Mazor Y, Noy R, Wels WS et al. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts. Cancer Lett 2007; 257: 124–135.
Du X, Nagata S, Ise T et al. FCRL1 on chronic lymphocytic leukemia, hair cell leukemia and B-cell non-Hodgkin's lymphoma as a target of immunotoxins. Blood 2007; Sept 25 Epub.
Filpula D, Yang K, Basu A et al. Releasable PEGylation of meso-thelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Bioconj Chem 2007; 18: 773–84.
Kreitman RJ, Squires DR, Stetler-Stevenson M et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23: 6719–29.
Powell DJ, Felipe-Silva A, Merino MJ et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 2007; 179: 4919–28.
Dang NH, Pro B, Hagemeister FB et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin's lymphoma. Br J Haematol 2007; 136: 439–47.
Frankel AE, Surendranathan A, Black JH et al. Phase II clinical studies ofdenileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer 2006; 106: 2158–64.
Dang NH, Hagemeister FB, Pro B et al. Phase II study of denileu-kin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 4095–102.
Quintas-Cardama A, Kantarjian H, Verstovsek S. Treatment of systemic mastocytosis with denileukin diftitox. Am J Hematol 2007; 82: 1124.
Kerl K, Prins C, Cerroni L, French LE. Regression of extranodal natural killer/T-cell lymphoma nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case. Br J Dermatol 2006; 154: 988–91.
Hathaway T, Subtil A, Kuo P et al. Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma. Clin Lymphoma Myeloma 2007; 7: 541–5.
Evens AM, Ziegler SL, Gupta R et al. Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma 2007; 7: 472–4.
Ho VT, Zahrieh D, Hochberg E et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 1224–6.
Talpur R, Jones DM, Alencar AJ et al. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126: 575–83.
Ghori F, Polder KD, Pinter-Brown LC et al. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab 2006; 91: 2205–8.
Park M, Liu GT, Piltz-Seymour J et al. Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy. Leuk Lymphoma 2007; 48: 808–11.
Dang NH, Fayad L, McLaughlin P et al. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin's lymphoma. Br J Haematol 2007; 138: 502–5.
DiVenuti G, Nawgiri R, Foss F. Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated acute T-cell leukemia-lymphoma. Clin Lymphoma 2003; 4: 176–8.
Litzinger MT, Fernando R, Curiel TJ et al. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood 2007; 110: 3192–201.
Mahnke K, Schonfeld K, Fondel S et al. Depletion of CD4+ CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 2007; 120: 2723–33.
Rainov NG, Soling A. Technology evaluation: TransMID, KS Biomedix/Nycomed/Sosei/PharmaEngine. Curr Opin Mol Ther 2005; 7: 483–92.
Weber FW, Floeth F, Asher A et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 2003; 88: 93–103.
Garland L, Gitlitz B, Ebbinghaus S et al. Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J Immunother 2005; 28: 376–81.
Hassan R, Bullock S, Premkumar A et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007; 13: 5144–9.
Hassan R, Broaddus VC, Wilson S et al. Anti Mesothelin immu-notoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xeno-grafts. Clin Cancer Res 2007; 13: 7166–71.
Zhang Y, Xiang L, Hassan R et al. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci USA 2007; 104: 17099–104.
Coffield S, Boyer A, Culp L et al. Intraprostatic treatment of patients with locally recurrent prostate cancer with the PSA-activated protoxin PRX302. ASCO GU Meeting, Feb 14–16 2008, Orlando, FL. Abstract no. 20172.
Kunwar S, Prados MD, Chang SM et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007; 25: 837–44.
Sampson JH, Raghavan R, Brady ML et al. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro Oncol 2007; 9: 343–53.
Frankel AE, Liu JS, Rizzieri DA et al. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma, in press.
Liu TF, Urieto JO, Moore JE et al. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Exp Hematol 2004; 32: 277–81.
Azemar M, Djahansouzi S, Jager E et al. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2. Breast Cancer Res Treat 2003; 82: 155–64.
von Minckwitz G, Harder S, Hovelmann S et al. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA spe-cific for the ErbB2/HER2 receptor in patients with advanced solid malignancies. Breast Cancer Res 2005; 7:R617–26.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Frankel, A.E., Woo, JH., Neville, D.M. (2009). Immunotoxins. In: Oldham, R.K., Dillman, R.O. (eds) Principles of Cancer Biotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2289-9_11
Download citation
DOI: https://doi.org/10.1007/978-90-481-2289-9_11
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-2277-6
Online ISBN: 978-90-481-2289-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)